« April 2005 | Main | June 2005 »

May 31, 2021

Montclair Streamlines Discharge Process with Patient Placement Systems

Montclair Baptist Medical Center in Birmingham, Alabama, is the latest medical facility to streamline patient discharge and placement with Web-based technology from Patient Placement Systems in Alpharetta, Georgia. - Patient Placement Systems is a Web-based application that connects hospitals, healthcare facilities and service providers throughout the patient care continuum, making the process of referring and placing a patient who requires care after leaving the hospital more secure, effective and timely. Montclair “determined the PPS system will expedite the discharge process, increase efficiency, and improve satisfaction of both patients and staff,” Montclair Case Management Director Carol Murphy said.

(PRWEB) May 31, 2021 -- Montclair Baptist Medical Center in Birmingham, Alabama, is the latest medical facility to streamline the patient placement process with Web-based technology from Patient Placement Systems in Alpharetta, Georgia.

“Discharge placement of patients is often time consuming, and requires contacting numerous nursing homes, home health agencies and other parties,” said Carol Murphy, Director of Case Management at Montclair. “We determined the PPS system will expedite the discharge process, increase efficiency, and improve satisfaction of both patients and staff.”

Patient Placement Systems is a Web-based application that connects hospitals, healthcare facilities and service providers throughout the patient care continuum, making the process of referring and placing a patient who requires care after leaving the hospital more secure, effective and timely. From searching for the appropriate provider, to securely transferring confidential medical information, to arranging patient transport, PPS streamlines the patient placement process. The PPS online, real-time solution helps healthcare institutions reduce length of stay and helps discharge planners do their jobs more effectively.

Murphy said Montclair Case Management “looked at several discharge placement systems. We chose PPS because the system is user-friendly, decreases the time spent on each case and provides tracking of our work.”

Montclair is a 496-bed medical complex located in Birmingham. The Montclair campus includes the Alabama Heart Institute at Montclair, outpatient rehabilitation and physician complex, a neuroscience center, a comprehensive mitral valve prolapse center, a 26-bed transitional care unit, a 27-bed rehabilitation unit and a 40-bed psychiatric unit. In fiscal 2004, the facility recorded 93,216 patient days. Montclair is a part of Baptist Health System, Inc., the largest health care system in Alabama.

Patient Placement Systems digitally connects all parties involved in referring and transferring patients from one facility to another through the PPS Network. The PPS Network improves information flow and communication so each party involved in patient transfer has the information they need, when they needed it. PPS is a part of Jackson Healthcare Solutions family of companies. For more information about PPS, visit www.patientplacement.com, or call (877) 742-0403.

Posted by Industrial-Manufacturing at 04:18 AM | Comments (0)

DataCore's FDA Module Selected by Large Life Sciences Manufacturers; Momentum Continues

DataCore Technology announced the selection of its FDA Module for Cyco AutoManager® Meridian by a global, tier-one pharmaceutical company for use in their numerous facilities world wide.

Exton, PA (PRWEB via PR Web Direct) May 31, 2021 -- DataCore Technology, a specialist in implementing electronic document management systems, announced the selection of its FDA Module for Cyco AutoManager® Meridian by a global, tier-one pharmaceutical company for use in their numerous facilities world wide. DataCore's popular FDA module enables organizations to quickly achieve FDA compliance with 21 CFR Part 11. Since the product's inception in 2002, DataCore has built a distinct portfolio of life sciences manufacturers that have successfully implemented the module to drastically improve compliance effectiveness and reduce residual compliance risk. This has proven to lead to significant cost-savings in the engineering operations of various life sciences companies both in the U.S. and abroad.

DataCore's FDA module is targeted at companies in the pharmaceutical, biotech and medical device markets that need to comply with 21 CFR Part 11 and other GMP requirements. The module is an out-of-the-box solution that hooks into the engineering data management engine of Cyco AutoManager Meridian. The combined solution provides a configurable environment with electronic signatures, automatic PDF/DWF renditions, a compliant audit trail, a User Manager with application login screen, enhanced security measures, and controlled print stamping.

"Our configurable solution supports FDA and GMP requirements to facilitate the specific needs of our diverse customer base," says Brian Sallade, President of DataCore Technology. "The momentum for our solutions has been growing. We believe that by providing robust functionality in an out-of-the-box solution, we appeal to a large number of pharmaceutical, biotech and medical device manufacturers."

"DataCore has been on the leading edge by providing their expertise in an affordable package," says Paul Bowman, Marketing Director of Cyco Software. "By offering our combined software solution with their unparalleled knowledge and consulting services, they fulfill the demand in a growing niche market."

Numerous life sciences companies have chosen to implement DataCore's FDA Module with Cyco AutoManager Meridian for a number of reasons, including:

* Save time with configurable, out-of-the-box set up
* Improve efficiency, productivity, and compliance through automation
* Reduce validation costs with an available GAMP 4 based validation package
* Enhance collaboration and document control with configurable workflows
* Leverage engineering documentation by integrating with other enterprise business systems, including MRO MAXIMO, SAP, and Documentum

DataCore Technology has partnered with Cyco Software reseller in the Americas and Europe to offer its FDA module to pharmaceutical companies around the globe. For more information, please visit http://www.data-core.com/pharmaceutical.htm.

About DataCore Technology
DataCore Technology specializes in implementing Electronic Data Management solutions for energy, government, manufacturing, and pharmaceutical organizations to help improve time to market, reduce asset maintenance costs, and comply with government regulations. The company operates with the highest degree of integrity, provides quality products and services, and maintains a steadfast commitment to excellence. For more Information, please visit www.data-core.com or call (800) 531-2287.

About Cyco Software
Cyco Software provides Engineering Data Management and Application Integration solutions for multiple vertical industries, including manufacturing, energy, government, pharmaceutical, retail and telecommunications. Cyco Software has almost two decades of industry experience with more than 16,000 clients and over 275,000 users in 50+ countries worldwide. The company has offices in the USA, UK, Germany, Italy, Korea, Russia and The Netherlands, and an extensive global network of established partners around the world. For more information, please visit www.cyco.com, or call (800) 323-2926 ext 110 (Americas) or +31 (0) 70 413-3700 (Europe).

Contact:
Brian Sallade
DataCore Technology, Inc.
(800) 531-2287
www.data-core.com
e-mail protected from spam bots

Posted by Industrial-Manufacturing at 04:17 AM | Comments (0)

SourceOne Healthcare Technologies, Inc. Signs Exclusive Distribution Agreement with Imaging Dynamics Co.(IDC) to Serve Government Accounts

SourceOne To Sell IDC’s Xplorer™ DR Systems to All Branches of the U.S. Military and U.S. Government Agencies

Mentor, OH / Calgary, Alberta, (PRWEB) May 31, 2021 -- SourceOne Healthcare Technologies, Inc. and Imaging Dynamics Company, LTD. (IDC TSXV: IDL), today announced the companies have signed an exclusive distribution agreement giving SourceOne exclusive rights to sell IDC’s Xplorer™ DR systems to all branches of the U.S. Military and U.S. Government Agencies.

SourceOne is the nation’s leading distributor of medical imaging systems, equipment, radiographic consumable supplies, and services to healthcare facilities. IDC manufactures and markets its innovative direct digital radiography (DR) solution to hospitals, imaging centers, specialty clinics, and orthopaedic centers. Both companies initiated a highly successful nationwide distribution agreement to serve Government as well as civilian customers in November 2004.

“We have a long and rewarding history of servicing the Government sector,” said Jerry C. Cirino, president and CEO, SourceOne Healthcare Technologies. “We are pleased to help Government customer’s transition from analog to digital solutions, first with OREX CR units, and now with IDC’s distinctive DR solution.”

“We are very excited about delivering our innovative, reliable, and affordable DR technology to Government customers,” said Darryl Stein, president and CEO, Imaging Dynamics Co. “SourceOne’s excellent reputation with the Government sector presents a solid opportunity to combine our individual strengths and meet the growing demand for digital radiography in this important marketplace.” He added, “Working closely with SourceOne’s experienced sales force, we will jointly serve Government customers ranging from the Federal Bureau of Prisons, Indian Health Services, and the Veterans Administration, to all branches of the U.S. Military, including the Navy, Air Force, Marines and Army.”

“During the past 18 months, SourceOne has delivered hundreds of OREX CR units to branches of the U.S. Military,” said Cirino. “To date, most of these units have been deployed in Iraq, Afghanistan and various military installations. Building on this success, we anticipate IDC’s innovative and affordable DR solution will prove to be equally successful in serving un-met needs in branches of the U.S. Military and non-military Government agencies, alike.”

About SourceOne Healthcare Technologies
Headquartered in Mentor, Ohio, SourceOne Healthcare Technologies is a leading provider of imaging equipment, radiographic supplies and services tailored to healthcare facilities including those transitioning to a digital imaging environment. Its broad equipment and consumables lines, e-logistics, sales professionals and field service engineers enable customers to turn to SourceOne as the best-in-class, single source for effective supply chain and medical imaging management. SourceOne is a privately held company of Platinum Equity, a global acquisitions firm specializing in the strategic operation of mission-critical companies. For additional information about SourceOne, visit www.sourceonehealth.com.

About IDC
IDC is based in Calgary, Alberta, Canada. IDC’s Xplorer technology is a patented, very high density (VHD) CCD based technology that provides an affordable, high-resolution digital capture device for x-ray imaging. IDC’s digital products eliminate the need for film in general radiography imaging. The Corporation has Health Canada approval, U.S. Food and Drug Administration marketing clearances, ISO 9001 and ISO 13485 certifications and CE Mark. For more information about IDC, visit www.imagingdynamics.com.

Posted by Industrial-Manufacturing at 04:16 AM | Comments (0)

Baxa Corporation Announces Direct Sales And Marketing Effort In Canada Beginning June 1

Baxa Corporation announces that it will be moving to direct marketing and sales in Canada as of June 1, 2005. For the past ten years, Baxa products have been sold through a distributor under the name of Baxa Canada. In that time, product marketing and technical support activities were done through the company’s corporate offices in Colorado. With its distributor contract expiring, Baxa decided to begin direct sales and marketing operations for all of North America from its US headquarters.

Englewood, CO (PRWEB) May 31, 2021 -- Baxa Corporation announces that it will be moving to direct marketing and sales in Canada as of June 1, 2005. For the past ten years, Baxa products have been sold through a distributor under the name of Baxa Canada. In that time, product marketing and technical support activities were done through the company’s corporate offices in Colorado. With its distributor contract expiring, Baxa decided to begin direct sales and marketing operations for all of North America from its US headquarters.

“We have in place an outstanding Canadian team to continue the growth of Baxa product sales in Canada,” notes Steve Welch, Vice President of Business Development. “A direct sales force in Toronto will allow us to continue to develop our success in Canada, while allowing us to provide better customer response.”

Most product orders for Canadian customers originate in the manufacturing headquarters. Beginning in June, customer support and contract management will be handled out of the Baxa corporate offices as well. Baxa Canada will maintain a distribution center in Toronto, Ontario to support shipment of back-up equipment, supplies, and manage product returns.

“We expect to continue providing the same excellent service our customers have seen from Baxa Canada over the past decade,” states Larry Grzebinski, General Manager, Canadian Operations. “Our team is working closely with Baxa home office associates to ensure a smooth transition.”

Baxa Corporation, a 2005 winner of the Governor’s Award for Exporting, has a subsidiary office in the United Kingdom, and sales offices in Denmark and Germany. About 20% of the company’s annual sales are outside the US, which experienced an increase of 29% in 2004 over the prior year. The new Canadian office supports the company’s goal of strengthening its presence in the global healthcare market.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom, Denmark, and Germany, and distribution partners worldwide. Further information is available at http://www.baxa.com.

Contacts:

Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 04:15 AM | Comments (0)

Milwaukee Firm Awarded Service Provider of the Year

Iverson Language Associates, Inc. was recently honored for its work in the translation industry with the 2005 ClientSide Excellence Award for Service Provider of the Year.

(PRWEB) May 31, 2021 -- Iverson Language Associates, Inc. was recently honored with the 2005 ClientSide Excellence Award for Service Provider of the Year. The award recognizes exceptional translation industry professionals that set high standards and develop innovative client- and industry-specific solutions. Steve Iverson, President/CEO accepted the award on behalf of the company at an awards ceremony held in New Orleans, Louisiana.

"We are honored by this recognition of our work, and thank the clients and colleagues who nominated and supported us, not only for this award, but also throughout the past 18 years. These awards recognize our ongoing commitment to quality and service,” states Steve Iverson, President/CEO.

Iverson Language Associates, Inc. was founded by Steve Iverson in 1986 (and incorporated in 1987). The original business model for the company was education: teaching foreign languages to international business professionals. Due to the language specialization of the business, the company received many inquiries for translation. As international business grew nationwide, so did the requests for translation − this eventually led Iverson to focus the business on managing document translation.

As a business owner, Iverson is an active member of both the translation industry and the business community. He serves on the board of the World Trade Center − Wisconsin (WTC WI), and is a founding member of the Association of Language Companies (ALC). He is also a member of the American Translators Association (ATA) and affiliated with a variety of international groups.

Headquartered in Milwaukee, Iverson Language Associates, Inc. works with companies nationwide to provide strategic solutions for managing document translation. Clients include companies and organizations that have an ongoing need to communicate business-critical information in multiple languages. For more information, please visit www.iversonlang.com.

Posted by Industrial-Manufacturing at 04:14 AM | Comments (0)

May 30, 2021

Baxa Corporation Receives Small Business Exporter Of The Year Award

Baxa Corporation was honored as Colorado’s Small Business Exporter of the Year at an awards ceremony held at the Denver Museum of Nature and Science on May 25, 2005. The award was presented by the Colorado Small Business Administration, and accepted by Baxa President and Chief Operating Officer, Jeff Baldwin.

Englewood, CO (PRWEB) May 30, 2021 -- Baxa Corporation was honored as Colorado’s Small Business Exporter of the Year at an awards ceremony held at the Denver Museum of Nature and Science on May 25, 2005. The award was presented by the Colorado Small Business Administration, and accepted by Baxa President and Chief Operating Officer, Jeff Baldwin.

“We appreciate the recognition for our efforts to champion Colorado exporting,” said Jeff Baldwin. “Baxa began exporting in 1985, and we use suppliers and partners worldwide.” Today, about 20% of the company’s sales are outside the United States. International sales growth for 2004 increased 29% over the previous year.

A family-owned business, Baxa is celebrating 30 years of operation in 2005. Headquartered in Englewood, Colorado, the company employs 300 associates to manufacture devices and systems used in hospitals and alternate-site facilities for safe and efficient preparation, handling, packaging and administration of fluid medications. Baxa products are sold direct through subsidiary and sales offices in the United States, Canada, the United Kingdom, Denmark and Germany; and through distribution partners worldwide.

This is the first year that Baxa Corporation has been nominated for a Small Business Administration award. The company joined eight other small business champions in categories such as Small Business Finance Champion and Women in Business Champion.

About Baxa Corporation
Founded in 1975, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.
About the Small Business Administration (SBA).

The U.S. Small Business Administration (SBA) was created in 1953 as an independent agency of the federal government to support small business concerns and strengthen the overall national economy. The Colorado District Office is responsible for the delivery of SBA's programs and services throughout Colorado. Further information is available at http://www.sba.gov/co/.

Contacts:

Marian Robinson, Vice President, Marketing, Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR, Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 03:26 AM | Comments (0)

Colorado BioScience Association Names Ed Wood Chairperson And Appoints Four New Board Members

Ed Wood, CEO of Summit Roundtable in Lakewood, CO, is the new Chairperson of the Board of Directors for the Colorado BioScience Association (CBSA). He was appointed at the Association’s 2005 Annual Meeting held in April. Wood assumes chairperson responsibilities from Ralph (Chris) Christoffersen, General Partner, Morgenthaler Ventures, Boulder, CO, office. Vice Chairperson of the board is Jack Wheeler, CEO of Microphage, Inc., Longmont, CO. In other action, four new board members were appointed, and nine existing board members reappointed, to three-year terms.

Denver, CO (PRWEB) May 30, 2021 -- Ed Wood, CEO of Summit Roundtable in Lakewood, was named Chairperson of the Board of Directors for the Colorado BioScience Association (CBSA) at its 2005 Annual All-Member Meeting held at Denver’s National Jewish Medical & Research Center in April. The announcement is made by Denise Brown, CBSA Executive Director, who says Wood assumes chairperson responsibilities from Ralph (Chris) Christoffersen, General Partner, Morgenthaler Ventures, Boulder office (http://www.morgenthaler.com/ventures).

Vice Chairperson of the CBSA board is Jack Wheeler, CEO of Microphage, Inc. (http://www.micro-phage.com), headquartered in Longmont. In other action, four new board members were appointed, and nine existing board members reappointed, to three-year terms.

The CBSA board is comprised of members from traditional biotechnology companies (20%), traditional medical device companies (20%), research organizations (10%), service providers (10%) and emerging companies (10%). The remaining 30% is based on need and opportunity according to association bylaws. New CBSA board members receiving three-year appointments include: Tom Miller, President, Emerging Medical Technologies; Tom Cycyota, President & CEO, AlloSource (http://www.allosource.org); Tom Roach, CPA, Ernst & Young (http://www.ey.com); and Maggie Chamberlin Holben, APR, Absolutely Public Relations (http://www.absolutelypr.com).

Those CBSA board members reappointed to three-year terms are: William Freytag, President & CEO, Myogen (http://www.myogen.com); Rick Jory, President & CEO, Sandhill Scientific (http://www.sandhillsci.com); Lynn Taussig, President & CEO, National Jewish Medical & Research Center (http://www.njc.org); John Eckstein, Director, Fairfield and Woods, P.C. (http://www.fwlaw.com); Brent Hinkston, Area Executive, IBM Life Sciences (http://www.ibm.com/industries/healthcare); Steve Onody, CEO, Onody Associates (http://www.onodyassoc.com); Clay Anselmo, President & COO, Reglera (http://www.reglera.com); Jack Wheeler, CEO, MicorPhage (http://www.micro-phage.com); and Paul Ray, President & CEO, Nervonix (http://www.nervonix.com).

About Ed Wood, CBSA Chairperson
Ed Wood is a seasoned executive, experienced in launching both high-technology products and successful careers. He received degrees in chemistry from Harvey Mudd College and business from the University of Colorado. He joined a small company (COBE Laboratories Inc.) in 1972. Starting with a career in manufacturing engineering, he added careers in research and development, manufacturing management, marketing, and sales. Eventually, as CEO of COBE, Wood led a team of people that created COBE BCT Inc. which eventually became the most dynamic, innovative and successful subsidiary of COBE, with well over $150 million profitable revenue annually. Wood’s current practice at Summit Rountable emphasizes executive coaching and corporate governance. You can learn more about Wood’s consulting firm at http://www.summitroundtable.com.

About Colorado BioScience Association
Colorado BioScience Association is a not-for-profit corporation providing services and support for Colorado’s growing biosciences industry. Colorado is carrying out an aggressive plan to grow the state’s bioscience industry into one of the country’s premier bioscience clusters. CBSA currently enjoys the support of 304 member organizations representing both bioscience companies and companies providing key services to the bioscience industry and research institutions in Colorado. The association’s main office is located in the Advance Colorado Center, 1625 Broadway, Suite 950, in Denver, plus satellite offices are maintained in the Fitzsimons Bioscience Park and at the Fort Collins Technology Incubator. A Colorado Springs satellite office is planned for the future. You can learn more about CBSA at http://www.cobioscience.com

Contacts:

Denise Brown, Executive Director,
Colorado BioScience Association,
303.592.4073,
E-mail: e-mail protected from spam bots

Maggie Chamberlin Holben, APR,
Absolutely Public Relations,
303.984.9801 or 303.669.3558,
E-mail: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 03:23 AM | Comments (0)

AAT Announces Better Cleaning for Plastic FOUPs, Carriers for Wafer Processing

Austin American Technology (AAT) has developed effective cleaning systems and solutions for plastic FOUPs (Front Opening Unified Pods), Front Opening Shipping Boxes (FOSBs), and other plastic wafer handling carriers and devices used in semiconductor processing.

(PRWEB) May 29, 2021 -- Austin American Technology (AAT) has developed effective cleaning systems and solutions for plastic FOUPs (Front Opening Unified Pods), Front Opening Shipping Boxes (FOSBs), and other plastic wafer handling carriers and devices used in semiconductor processing. The cleaning chemistries in AAT’s conveyorized or batch cleaning systems, plus effective media isolation technology effectively remove such contaminants as inks, fingerprints, oily spots, glue residue, and even silicone mold release agents used in initial plastic parts manufacture. The chemistries do not harm the plastics and will clean them to the required cleanliness (cleanroom) specified levels while preventing recontamination or contamination migration.

AAT’s conveyorized cleaning systems such as the HydroJet and MicroJet offer high-speed cleaning and high-velocity drying with blowers fitted with HEPA filters to preclude any re-contamination, a feature necessary in cleanroom environments and particularly in semiconductor wafer processing. Drying is fast, complete (especially FOUP doors), spot-free and residue-free, and the operator is not exposed to any of the cleaning chemistry.

AAT’s The Mega™ II is a revolutionary closed-loop, solvent regenerative, cleaning system ideal for the stringent demands of FOUP cleaning. This large-capacity batch system features quantitative ion detection and statistical process control capability and automated operation especially suited for the stringent demands of semiconductor processing. Mega™ II wash and rinse cycles incorporate a highly effective spray under immersion process, with strategically located venturi nozzles for maximum cleaning efficiency of odd-shaped parts and system components. The agitation can be controlled to handle hard to clean, tight tolerance part designs; an ultrasonics assist is available as an option for extremely tough cleaning requirements.

AAT cleaning systems for FOUPs and plastic carriers and parts offer closed loop fluids recycling and/or solvent regeneration in an environmentally responsible family of products with tight process control and flexibility. AAT cleaning systems also offer low cost of ownership and operation due to efficient operation, low solvent cost and reduced dragout, fast cycle times, and a variety of cleaning configuration options.

Austin American Technology is the recognized global leader in cleaning technology for industrial cleaning applications ranging from electronics manufacturing to specialized parts cleaning. For more information about AAT cleaners, chemistries, and other products, visit www.aat-corp.com, or contact the company at 12201 Technology Blvd. Austin, Texas 78727 USA, tel. (512)335-6400.

Posted by Industrial-Manufacturing at 03:19 AM | Comments (0)

May 28, 2021

Synthetic Cartilage Cleared for Sale in Canada

Medical device manufacturer, SaluMedica, has announced receipt of the Medical Device License from Health Canada for its SaluCartilage product. SaluCartilage is an cylindrical implant designed to replace small cartilage defects in the knee, shoulder and toe joints.

Atlanta, GA (PRWEB) May 28, 2021 -- SaluMedica, LLC, a pacesetter for orthopedic soft tissue solutions, today announced that it has received a Medical Device License from Health Canada for SaluCartilage™. Made from an organic polymer-based hydrogel, SaluCartilage™ is the company’s first implant for cartilage replacement. SaluCartilage™ has been developed to restore a smooth, articulating joint surface by replacing small, focal lesions of cartilage. The Health Canada license allows SaluMedica to begin selling SaluCartilage in Canada.

Health Canada approval complements the CE Mark that SaluMedica received in 2002 allowing distribution of SaluCartilage™ in the European Union. Since that time SaluCartilage™ has been used to replace small (approximately dime-sized) cartilage defects in the knee, toe, and shoulder.

“We hear daily from patients looking for a solution to their joint pain and immobility,” says David Ku, MD, PhD, President and CEO of SaluMedica. “We’re energized by the positive outcomes coming out of Europe and we are optimistic about expanding these successes in Canada.” The company is currently implementing plans to expand distribution and use of the product throughout the European Union and Canada.

About SaluMedica, www.salumedica.com
Developed by Atlanta-based medical device manufacturer, SaluMedica, SaluCartilage is the first orthopedic product made from Salubria® biomaterial, the Company’s platform technology. SaluMedica's team of physicians, scientists, engineers, and industry specialists is dedicated to developing new applications of Salubria biomaterial and bringing them to market to fill the long-standing need for biocompatible products replacing damaged soft tissue.

This press release may contain forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those discussed in this release, due to, among other things, the research, development, and market risks which could adversely affect the company’s timeline for clinical trials, regulatory approval and if such approval is received, time to market thereafter. SaluCartilage is not approved for sale by the U.S. Food and Drug Administration, nor available to treat patients in the United States.

Posted by Industrial-Manufacturing at 12:02 AM | Comments (0)

May 26, 2021

Aperon Biosystems Raises $15.3 Million in Series B Financing

Canaan Partners led the round of financing and was joined by Draper Fisher Jurvetson and current investors, Onset Ventures and Alliance Technology Ventures.

Palo Alto, CA (PRWEB via PR Web Direct) May 26, 2021 -- Aperon Biosystems, a leading innovator in asthma management, announced the completion of a $15.3 million round of financing. Canaan Partners led the round and was joined by Draper Fisher Jurvetson and current investors, Onset Ventures and Alliance Technology Ventures.

Aperon is developing the first practical in-home monitor for daily measurement of exhaled nitric oxide (NO) for the management of asthma. The funds from this financing will be used to finalize development of the commercial device and initiate clinical trials.

"Since its initial funding two years ago, Aperon has developed and demonstrated an innovative product that has the potential to provide significant clinical benefits to a population of asthma sufferers. This type of innovation represents exactly what we seek for companies in our portfolio," commented Wende Hutton, Venture Partner with Canaan Partners. Ms. Hutton will join the Aperon Board of Directors.

Asthma is a chronic inflammatory disease of the airways in the lungs affecting more than 18 million people in the U.S. Exhaled nitric oxide has been shown to be a marker for inflammation and provides a means for monitoring the patient's response to anti-inflammatory medications.

"Currently, physicians rely largely on symptoms to manage their patients and have little in the way of either management or diagnostic tools that are inexpensive or practical to use," commented John Kaiser, CEO of Aperon Biosystems. "Based on the powerful benefits this monitoring solution can bring to patients with asthma, Aperon has the potential to impact the management of asthma in much the same way that monitoring glucose has had an impact on the management of diabetes.”

About Asthma
Controlling inflammation is the central focus for managing the underlying disease of asthma and regular use of anti-inflammatory medications is now the mainstay for treatment of symptoms. Clinical research shows that monitoring inflammation on a regular basis to adjust anti-inflammatory medication could significantly improve disease management, resulting in reduced severity of symptoms, fewer exacerbations and optimized drug usage in individual patients. A non-invasive monitor to assess levels of inflammation has the potential to reduce medical costs while improving the quality of life for asthma patients.

About Aperon Biosystems
Aperon Biosystems is a privately held, venture-backed medical device company based in Palo Alto, CA. Aperon was founded in 2001 to develop a biosensor platform utilizing a patented Sol-Gel technology for the highly sensitive detection of selected analytes. The first application of this technology is a non-invasive monitor for the daily measurement of exhaled nitric oxide, suitable for use at physicians' offices and at home, for the management of asthma.
For more information, visit the Company’s website at www.aperon.com.

Media Contact:
Jean Nelson
Aperon Biosystems, Inc.
650-739-0910 x111
e-mail protected from spam bots

Posted by Industrial-Manufacturing at 02:46 AM | Comments (0)

Wanna Lose Weight? Get a Dreamhelmet

The results of recent scientific studies make it likely that using the Dreamhelmet, a combination sleep mask sound-blocking pillow, may aid weight loss by helping you sleep better.

(PRWEB) May 26, 2021 -- University of Chicago researchers reported in the December 7 (2004) issue of the Annals of Internal Medicine that insufficient sleep causes changes in levels of hormones that regulate hunger, making a person crave fattening foods,


The study is believed to be the first one to show that sleep is a major regulator of the hormones ghrelin, which triggers hunger, and leptin, which tells the brain when it’s had enough food. This affirms a quote by Jim de Cordova, creator of the Dreamhelmet, a patented sensory deprivation device: “If you don’t sleep – you must eat, and vice-versa.”

Both sleep deprivation and the percentage of Americans fighting obesity have been increasing since the 1960s. According to the National Sleep Foundation, Americans are averaging about two hours less sleep per night since that time. De Cordova believes these two trends are more than just casual bedfellows, and are aggravated by an increasingly frantic and noisy society.

De Cordova states: “Just see a film from the ‘60s – everybody had long hair and was slim! People in the ‘60s thought about peace, meditation, the environment, personal development, most of which is ignored by today’s trash culture. To lose weight and be healthy, a person needs to slow down, think about what’s really important, and learn to sleep right. Turn the TV off! – get a Dreamhelmet to pillow the head - block out light and sound. Slim and Healthy start with better sleep.”

Blocking light and sound and providing a pillow so the wearer can sleep anywhere, the Dreamhelmet has secret pockets near the temples that contain foam ear plugs. These pockets can hide credit cards, money, valuables, spare car or house keys or an alarm watch for a personal wake-up signal. The Dreamhelmet also converts to a simple small pillow, attachable pillow, hand warmer or muff.
100% cotton cradles the head and a choice of several attractive fabrics grace the outside. The Dreamhelmet costs $29.95 plus shipping. The direct 24 hour order number is (888) 918-5630. The website is www.dreamhelmet.com.

Posted by Industrial-Manufacturing at 02:44 AM | Comments (0)

Introducing Hoodia-Dietpills.com

Hoodia-Dietpills.com today announced the launch of a new Web site offering high quality Hoodia Gordonii products.

(PRWEB) May 26, 2021 -- Hoodia-Dietpills.com today announced the launch of a new Web site offering high quality Hoodia Gordonii products. The site is located on the World Wide Web at http://www.hoodia-dietpills.com.

The Web site provides Hoodia Gordonii for sale through a convenient online catalog. It also provides much information on the benefits of Hoodia, as well as research, its history, recommended dosage, possible side effects and more. (To learn more about the history of Hoodia, visit http://www.hoodia-dietpills.com/h_gordonii_history.htm ).

Hoodia is a natural substance that stops hunger and improves energy levels, without that “jumpy feeling”. As such, it has made a sensation in alternative medicine and is being used by an increasing number of people worldwide.

Hoodia can be very hard to identify because it looks so similar to other Hoodia succulents of the same family. For this reason, one must buy products made only from genuine Certified Pure South African Hoodia Gordonii. All Hoodia Gordonii 100% Pure Diet Pills sold by Hoodia-Dietpills.com come with a full No-Nonsense Money-Back Guarantee.

Hoodia gordonii is a plant found in the dry regions of the Southwestern African continent. It is now on the verge of making history in the fight against severe obesity. The plant is a genus belonging to the family Asclepiadaceae, which consists of about 20 species. The plant has become famous as an extremely effective hunger and thirst suppressant and has proven invaluable to those seeking to lose weight.

One Hoodia believer was quoted on the site: "Of all the diet pills I've tried, natural and otherwise there is nothing that comes even close. I can surely say Hoodoba diet pill is my savior. I lost 44 pounds in 10 weeks flat. I have just one question. I have just one question. Why weren't these pills made available sooner?”

Learn more about Hoodia at http://www.hoodia-dietpills.com/ , or read testimonials on its effectiveness at http://www.hoodia-dietpills.com/hoodia-diet-pills-testimonials.htm .

Posted by Industrial-Manufacturing at 02:44 AM | Comments (0)

Research and Markets: Global Medical Device and Equipment Market Expected to Grow Steadily By Around 4.6% Over Next Five Years

Research and Markets (http://www.researchandmarkets.com/reports/c17978) has announced the addition of The World Medical Market Report 2005 - Current Trends & Future Prospects to their offering.

Dublin (PRWEB) May 26, 2021 -- Research and Markets (http://www.researchandmarkets.com/reports/c17978) has announced the addition of The World Medical Market Report 2005 - Current Trends & Future Prospects to their offering.

The global medical device and equipment market is expected to grow steadily by around 4.6% over the next 5 years. The market continues to be led by the USA where demand will be strong. However this will be tempered by poor economic performance and cost containment in Europe and Latin America. Many Asian markets have fully recovered from the economic crisis and are now performing strongly, as are leading central and east European countries as they enter the EU.

So what, practically, does that all mean?
For planners, marketers, sales and general management, being able to plan effectively requires a detailed knowledge of which markets and market sectors are growing, and the national/regional context of that growth.

This completely updated report - The World Medical Markets Report 2005: Current Trends & Future Prospects - will be of interest to everyone operating or analyzing international medical device and equipment markets.

In over 230 information-packed pages it provides a wealth of difficult-to-source data from hundreds of national and pan-regional governments and organisations.

Easily answer questions such as:
-What is the estimated size of the global device industry in 2010?
-Which Asian countries offer the best opportunities in terms of market growth and in what sectors?
-What are the prospects for syringes, needles and catheters in Vietnam, Malaysia and Thailand?
-What growth can be expected in the central European economies?
-How did the Brazilian orthopaedic market perform in 2004, and what is its estimated value in 2007 & 2010?

The report provides market size and growth for the whole medical device and equipment market as well as detailed figures for 16 product sectors from 2005-2010. Also included in this report are global & regional overviews of the market, an analysis of the performance of 100 leading medical device companies together with key demographic data.

For more information visit http://www.researchandmarkets.com/reports/c17978

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980

Posted by Industrial-Manufacturing at 02:42 AM | Comments (0)

May 25, 2021

Cool Athletes in Hot Texas Soccer Action

Arctic Heat Cooling Vests available to keep athletes cool at the 2005 Texas Shootout in hot and humid Houston, Texas.

(PRWEB) May 25, 2021 -- Over 250 of the Nation’s top junior girl’s soccer teams, are about to travel to Texas to compete in the 18th Annual Texas Shootout, June 3-5. With Houston temperatures already hovering in the mid 90s, the action at this showcase event is sure to be hot and frantic. To allow the young elite athletes to “cool down” and “fire up”, Arctic Heat body cooling vests are being made available at this year’s event via the medical staff.

The 2005 Texas Shootout will feature around 3000 young female athletes giving 100% to impress the large number of college scouts in attendance. Medical staff will be at each of the venues to help treat the sick and injured athletes. This year the Arctic Heat Cooling Vests, Cooling Neck Wraps, Cooling Tubes and Cooling Blankets will be ready, to help treat those athletes who struggle in the heat.

“Each year at the Shootout, my staff & I treat a couple dozen athletes who get some form of heat exhaustion/heat illness. The Arctic Heat body cooling vests will be used to cool down athletes who become adversely affected by the hot & humid weather in Houston,” said Tom Dolan, Certified & Licensed Athletic Trainer & Sr. Vice President of Tomball Regional Hospital and in charge of the Texas Shootout's medical team.

The ice cold vests are ideally suited to soccer by allowing players to pre-cool before the game and then aiding in recovery during half time. The cool vests were used by the English and Uruguay National teams during the 2002 Soccer World Cup, and only last week the Australian National Men’s Soccer team joined the list of elite sporting teams to purchase the product.

The lightweight Arctic Heat Cooling vest works using a two stage cooling process. The vests contain a gel-like substance that can be frozen or chilled, and will maintain that temperature for up to 2 hours. The cooling vests are manufactured using Woolmark's Sportwool fabric which incorporates Vapor Management Technology.

The Arctic Heat USA body cooling vest which was used during the 2004 Olympics and is currently being used by the military in Iraq, comes in a large range of sizes and retails for $174.95. It can be purchased online from Arctic Heat USA www.arcticheatusa.com . More information about the 2005 Texas Shootout can be found at www.challengesoccer.com.

Posted by Industrial-Manufacturing at 03:35 AM | Comments (0)

May 23, 2021

Family Business Experts Credits Family Business Synergy As Key To Baxa Corporation’s Success

Baxa Corporation is featured in a recently published “Family Business Experts” profile detailing the key to the company’s 30 years of success in product innovation and customer responsiveness. The company was selected as the featured family business for the Family Business Institute’s (FBI) top-ranked Internet site, because Baxa met criteria as both a positive family and a business success story. The profile details the company’s 30 years of success in product innovation and customer responsiveness, crediting that success secret to family business synergy.

Englewood, CO (PRWEB) May 23, 2021 -- Baxa Corporation is featured in a recently published “Family Business Experts” profile detailing the key to the company’s 30 years of success in product innovation and customer responsiveness. The company was selected as the featured family business for the Family Business Institute’s (FBI) top-ranked Internet site, because Baxa met criteria as both a positive family and a business success story. The profile details the company’s 30 years of success in product innovation and customer responsiveness, crediting that success secret to family business synergy.

“One of the requirements necessary for family business success is maintaining profits while sorting out succession plans and balancing family vs. business demands,” says Don Schwerzler, founder of Atlanta-based Family Business Institute. “Baxa Corporation, as a business and as a family, maintains a synergy that any business would be thrilled to have.”

The Baxa Corporation Family Business Profile is found at http://www.family-business-experts.com/baxa.html.

Brian Baldwin founded Baxa Corporation in 1975 with business associate Ron Baxa. An entrepreneur and inventor, Brian had already established several other technology businesses serving the healthcare market. Over the years, Baxa grew through its founders’ focus on developing products that reduced the opportunity for medication errors and streamlined fluid handling processes. Through Brian’s leadership, the company introduced a number of “firsts” for pharmacy such as the first pharmacy pump and the first automated compounder that delivered both macro- and micro-volume ingredients.

Businesses have life cycles as products do, and at some point the entrepreneurial spirit that drives early success needs to give way to a focus on strategic development. That opportunity came when Brian’s son, Greg Baldwin, joined the company in 1993 to lead its sales and marketing teams. Now Chairman and CEO, Greg is a strategic thinker who brought a business focus to Baxa, developing a strong corporate leadership team backed by a technical direct sales team that has resulted in strong sales growth and profit performance.

Today, Greg leads the company with his younger brother, Jeff Baldwin, President and COO. Jeff, a bio-technical engineer, is a detail-oriented and analytical thinker, the perfect complement to his brother’s leadership style. Brian continues working as an intellectual and innovative spark for the research and development efforts at Baxa.

That kind of family business success story is exactly what Don Schwerzler hopes to foster through his work at Family Business Institute. “We provide family businesses with the tools to develop and implement succession and exit strategies, and a team of experts to assist with day-to-day issues at these unique businesses,” notes Schwerzler. Family-owned businesses can find the Baxa story, along with other Success Strategies for almost every concern that confronts a family in business together at the Web site, http://www.family-business-experts.com.

Family Business Experts is the highest ranked family business resource web site on the Internet. It is a content-rich site that in April 2005 attracted more than 50,000 page views and visitors from 125 different countries.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

About Family Business Institute
Nationally recognized Family Business Institute, Inc. was organized in the early 1980s to pioneer a multi-disciplinary approach to solving the unique and complex problems impacting family businesses. Their corporate logo of three interconnected circles represents the three major systems that family businesses must master to be successful. The first circle represents family; the second the business system; and the third represents the individual – a member of the other two systems. For more information, visit the company’s Web site (Family Business Experts) at http://www.family-business-experts.com.

Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR,
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 07:16 AM | Comments (0)

Colours Wheelchairs to Expand in the Middle East

Colours Wheelchairs is rapidly expanding and is eying new markets in the Middle East. Colours and its President, John Box, is the cover story of Fortune Small Business for May 2005

Amsterdam, The Netherlands & Anaheim, CA (PRWEB) May 23, 2021 -- Colours Wheelchairs is unique in the wheelchair industry: Colours focus is on esthetics and comfort. A well known brand in the USA, Colours is one of the fastest growing brands in the active wheelchair market, with much of its growth coming internationally. Colours is now seeking distributors in Turkey and The Middle East.

According to company sources, Colours’ international sales are developing due to its attractive range of Adult Everyday, Pediatric and Sports wheelchairs and aggressive international expansion strategy. For example, its Spazz G is one of the lowest priced active wheelchairs on the market. Distributors of disability products from Europe to Asia are signing up to obtain exclusive rights and Colours is now turning its attention to new markets in the Middle East.

Colours’ rapid growth is receiving a great deal of attention in the business community. The president of Colours John Box, a disabled entrepreneur, is the cover story of Fortune Small Business magazine for May 2005: http://www.fortune.com/fortune/fsb/information/fsb_current.

Established distributors of disability products in Turkey and The Middle East are encouraged to contact Dr. Gene Emmer of Med Services Europe.

About Colours ‘N Motion:
Colours is considered a leader in the rehabilitation industry for its design of innovative everyday, sport and pediatric wheelchairs. Colours’ wheelchairs are lightweight, adjustable and customizable. At 14.5 pounds (6.6 kg) the custom-designed Zephyr is one of the lightest wheelchairs on the market. The Boing! is the first wheelchair on the market with four-wheel independent suspension. Colours is disabled owned and operated. For more information: www.ColoursWheelchair.com

About Med Services Europe:
Med Services Europe B.V. is based in Amsterdam, The Netherlands and specializes in Sales, Marketing and Business Development services for the Pharmaceutical, Diagnostic and Medical Equipment Industry, and is Colours Represntative in Europe. Distributors are encouraged to contact Dr. Gene Emmer of Med Services Europe. For more information: www.MedServicesEurope.com Telephone: +31648566707 (in Amsterdam)

Posted by Industrial-Manufacturing at 07:15 AM | Comments (0)

Theramedix Launches Premiere Line of Enzymes to Health Care Professional Market

There's exciting news in the nutraceutical industry. Theramedix has rolled out its premiere line of plant-based enzymes today. Patients can now request this potent line of enzymes from their health care practitioners. This is not an over the counter brand.

Orland, FL (PRWEB) May 21, 2021 -- Theramedix announced the launch of a premiere line of enzymes to the professional health care practitioner market today at the ACAM 63rd International Educational Conference on Complementary, Alternative and Integrative Medicine in Orlando, Florida. The Theramedix high potency plant-based enzymes will now be available to health care practitioners, nationwide. Theramedix is a subsidiary of Enzymedica, a company that has provided high quality enzymes to the retail market since 1998 and is marked by SPINS research as the top retail line nationwide. The Theramedix line is proven to be the highest potency brand and is not available over the counter. It is expected that practitioners will engage as full partners in the promotion and use of these products due to the integrity of the product-line and the exclusive Thera-blend ™ system for the top four categories of enzymes: protease, lipase, amylase and cellulase. Through Thera-blend technology, each of these categories is represented by multiple enzymes, guaranteeing higher activity and natural integrity as opposed to other brands in the HCP market.

“Enzymes can provide many health benefits, but the benefits are only as effective as the delivery system. Why formulate something that does not work optimally in the body?” said Kalyna Hanover, Director of Theramedix. “The Thera-blend technology is a true innovation in that it offers genuine functional benefits. Health care professionals no longer have to question whether a particular enzyme is working in various pH levels throughout the digestive system. We have optimized enzyme activity in a wider pH range, while continuing to focus on efficacy.“

“We are very excited to partner with health care professionals,” said, Tom Bohager, CEO of Theramedix. “They have come to the right place, because Theramedix’s entire focus and purpose is enzymes. We are the experts of our niche and this is a pure, highest potency, broad spectrum line of enzyme formulations, which has been missing from their healthcare practice.” Unlike most of their competitors, Theramedix does not make vitamin, herb or mineral supplements.

Theramedix, a subsidiary of Enzymedica, formulates a premiere line of plant based pharmaceutical grade enzymes to health care professionals. Theramedix offices are located in San Francisco, California and the distribution facility is in Venice, Florida. Log onto www.theramedix.net. Media please contact Connie St. John at 415-454-2243.

Posted by Industrial-Manufacturing at 07:14 AM | Comments (0)

May 19, 2021

DDL West Addresses Declining CA Packaging Standards - Helps Manufacturers Maintain Package Integrity & Contain Costs

DDL West addresses declining packaging standards in California by helping manufacturers maintain package integrity and contain costs.

Costa Mesa, CA (PRWEB) May 19, 2021 -- http://www.testedandproven.com - DDL West, a CA-based package, product and material testing laboratory is addressing declining packaging standards in California by helping manufacturers maintain package integrity and contain costs.

California-based medical device manufacturers are increasingly struggling to maintain the integrity of their packaging while staying within budget.

“Many CA-based manufacturers are cutting down on the amount of testing they do in order to save money,” said Michael Foster, DDL West Package Engineer. “Instead of testing 30 package samples, they may only test 10, which results in a much lower confidence level.”

Packaging is not only failing integrity testing due to cost cutting, but also because many manufacturers are choosing the wrong type of packaging for their product. Since the majority of medical devices have sharp edges or points, it is vital to choose packaging that cannot be perforated.

“DDL West is educating clientele via its growing suite of complimentary PackServices,” said Foster. “DDL West offers comprehensive consultation to identify manufacturers’ individual package testing requirements and to determine the best value for their testing dollars.”

DDL West is helping medical device manufacturers maintain the integrity of their packaging with advice on how to:
- Choose the right materials for their packaging
- Submit the correct number of package samples for a 90-95% confidence level
- Maximize on their package testing investment
- Eliminate costs of re-testing

For expert advice on maintaining cost effective package integrity, visit http://www.testedandproven.com or call Mike Foster at (714) 979-1712 ext. 16.

About DDL West:
DDL West offers expert package testing, product testing and material testing services including Shock testing, vibration testing, tensile testing, leak testing and validation. DDL package testing clients find value through its zero-cost package testing consulting service, Pack-Advice.

Posted by Industrial-Manufacturing at 03:29 AM | Comments (0)

May 18, 2021

Digital Control Systems Launches the New Model 90 PID Controller

The newest PID controller from Digital Control Systems. An ideal control for OEM Equipment Manufacturers servicing the global marketplace. The Model works from 80 - 280 VAC without modification, and can accept multiple inputs, including RTD probes, and thermocouples.

(PRWEB) May 18, 2021 -- Ideal for Equipment Manufacturers the Digital Control Systems, Inc. Model 90 PID Controller is the latest evolution in the Multistat series of temperature controls. Designed for the global equipment market, the Model 90 PID Controller can operate from direct or alternating current power mains from 80 to 280 volts, so it can be used anywhere in the world without modification or adjustment. “We developed the Model 90 in response to our customers who sell to the international market and who had to juggle the logistics involved with the various voltage requirements around the world -- in addition to flexible load and voltage requirements, the Model 90 is robust and reliable,” said Mike Mueller, President and founder of Digital Control Systems, Inc.

This single-channel PID controller will accurately control single electrical loads of up to 15 Amps. All of the Model 90 control electronics and the user interface are built on a compact (13.5 x 6 cm) circuit board for easy mounting and integration into medical, laboratory, and industrial equipment. Large bright LED digits make the display easy to read from across the room.

Recognizing the considerable safety benefits to be gained from reducing high voltage wiring, Digital Control Systems, Inc, designed the Model 90 to feature a second smaller power module that can be located near the output. This eliminates the need to run high current wiring to the front control panel. As an additional benefit, this power module is connected to the main circuit board with a low voltage cable. A second power module can also be added to control an auxiliary load.

The Model 90 offers more options than similar controls in the Multistat™ family of temperature controls. The extensive options available for the Model 90 make it easy for equipment manufacturers to differentiate similar products. Options such as an audible alarm, two pole alarm relay, RS-232, or a timer can be added individually based on application requirements. The optional RS-232 interface feature enables remote operation and data logging. “Rather than bundle all of the available features, we prefer to offer our customers options on a one by one basis, this way they aren’t paying for features they aren’t going to use”, adds Mike Mueller.

The Model 90 temperature controller works with a variety of inputs. For direct temperature control the Model 90 can be used with economical IC sensors (for operation below 100 °C), RTDs, or type ‘J’ and ‘K’ thermocouples. A direct voltage (5 volts Max) input configuration is also available for control of parameters measured by external sensors such as humidity or CO2.

Digital Control Systems Inc. is based in Portland, Oregon and has been designing and manufacturing a wide array of temperature controllers, motor speed controls, CO2 Sensors and Custom Products since 1984. The DCS family of products includes, the AirSense CO2 Monitor, Laboratory CO2 Sensor solutions, the Servomax DC Motor Speed Control, and the Multistat line of Temperature Control products. Technical information and brochures for the Model 90 and all of the Digital Control Systems products can be accessed online at www.dcs-inc.net.

Posted by Industrial-Manufacturing at 04:12 AM | Comments (0)

May 16, 2022

University of Pittsburgh Medical Center Selects Galvanon's MediKiosk and Enterprise WayFinding Solutions to Simplify the Patient Check-in and Registration Process

Kiosks will enable the hospital to speed the check-in process, improve registration accuracy, eliminate redundant paperwork and minimize wait times

Maitland, FL (PRWEB via PR Web Direct) May 16, 2022 -- Galvanon, the patient experience company, today announced that the University of Pittsburgh Medical Center (UPMC), the largest healthcare provider in Western Pennsylvania, has selected its MediKiosk™ and Enterprise WayFinding solutions. Under the terms of the agreement, UPMC will pilot MediKiosk at its Montefiore location to automate patient check-in and enhance the patient registration process.

Powered by Galvanon's state-of-the-art software, the check-in kiosks will allow patients to quickly identify themselves and receive prompt and accurate directions to the appropriate function or location within the facility. The interactive registration kiosks will complement the patient registration process by engaging the patient to view and confirm demographic and insurance information, electronically sign documents and make co-payments. This self-service approach will enable the hospital to speed the check-in process, improve registration accuracy, eliminate redundant paperwork and minimize wait times.

"At UPMC, we strive to provide the best possible experience for our patients and visitors. By implementing these self-service kiosks, Galvanon allows us to tailor each visit to the patient’s unique needs," said Mark Hopkins, chief information officer, academic and community hospitals, at the University of Pittsburgh Medical Center. "With the addition of this technology, we plan to make tremendous strides in not only creating more patient-friendly facilities but also in strengthening patient relationships."

"UPMC is a recognized leader in the use of healthcare information technology, and we are pleased to be a part of their enterprise-wide technology strategy," said Clynt Taylor, chief executive officer of Galvanon. "The implementation of patient self-service kiosks represents a big step forward for the organization's patient satisfaction initiatives, and we commend UPMC for its visionary approach to improving the delivery of healthcare to its patients."

Galvanon's MediKiosk is part of a comprehensive suite of products that allows hospitals and clinics to provide patient self-service capabilities such as pre-registration via the Web, online BillPay and eClipboards™, Galvanon's wireless patient check-in solution.

About UPMC
The University of Pittsburgh Medical Center (UPMC) is a non-profit, comprehensive academic health care system affiliated with the University of Pittsburgh Schools of the Health Sciences. Their combined mission is to provide quality patient care, educate the next generation of health care professionals and advance biomedical knowledge through basic and clinical research.

UPMC is considered the leading integrated health care delivery system in western Pennsylvania and one of the largest in the United States. UPMC has more than 39,000 employees, making it the largest employer in western Pennsylvania. With a network of 19 tertiary, specialty and community hospitals, located in both rural and urban settings; 400 outpatient sites and physician practice offices throughout western Pennsylvania; and several nursing, personal care and long-term care facilities, its services represent the full continuum of care.

About Galvanon, Inc.
Galvanon helps healthcare organizations enhance the patient experience at home, in the hospital, and in the physician's office through innovative solutions such as kiosks, Web self-service applications and technology that streamlines everyday patient interactions and improve patient flow through the healthcare process. For more information, visit www.galvanon.com/healthcare.

Press contact:
Cathi Hilpert
e-mail protected from spam bots
770-663-6343, ext. 223

Sales contact:
Chakri Toleti
e-mail protected from spam bots
407-701-6975

Posted by Industrial-Manufacturing at 03:20 AM | Comments (0)

Baxa Corporation Awarded Colorado Governor’s Award For Excellence In Exporting

Baxa Corporation has been chosen to receive the Governor’s Award for Excellence in Exporting in an announcement made last week by Governor Bill Owens. The award honors Colorado companies that have made significant contributions to exporting during the past year. Award presentations will be made at the World Trade Day Dinner on May 18, 2021 at the Grand Hyatt in downtown Denver. Baxa Corporation was honored in the large-size manufacturing company category.

Englewood, CO (PRWEB) May 16, 2022 -- Baxa Corporation has been chosen to receive the Governor’s Award for Excellence in Exporting in an announcement made last week by Governor Bill Owens. The award honors Colorado companies that have made significant contributions to exporting during the past year. Award presentations will be made at the World Trade Day Dinner on May 18, 2021 at the Grand Hyatt in downtown Denver. Baxa Corporation was honored in the large-size manufacturing company category.

Celebrating 30 years of operation in 2005, Baxa is a family-owned business headquartered in Englewood that employs approximately 300 associates. The company manufactures innovative devices and systems used in hospitals and alternate-site facilities for safe and efficient preparation, handling, packaging and administration of fluid medications. Baxa products are sold direct from subsidiary and sales offices in the United States, Canada, the United Kingdom, Denmark and Germany; and through distribution partners worldwide.

“Baxa began exporting in 1985,” notes Greg Baldwin, company Chairman and CEO. “We recognized early on the power of international markets and their potential for growth.” Today, about 20% of the company’s sales are outside the United States. International sales growth for 2004 increased 29% over the previous year.

The Governor’s Award for Excellence in Exporting has been presented annually since 1970, recognizing Colorado companies that demonstrate a commitment to international trade. This is the first year that Baxa Corporation has been nominated. The company joins other Governor’s Award winners in the small-size manufacturing, agriculture and service categories.

About Baxa Corporation
Founded in 1975, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

About the Colorado International Trade Office
The Colorado International Trade Office (ITO) is a state agency responsible for assisting Colorado companies with all aspects of exporting, including counseling, protocol, leading trade missions, and conducting trade shows abroad. By promoting Colorado exports and attracting foreign investment, the ITO helps to build Colorado’s identity as an international business center. Further information is available at http://www..state.co.us/oed/ito/index.html.

Contacts:
Marian Robinson, Vice President, Marketing, Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR, Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 03:19 AM | Comments (0)

May 15, 2022

AmniSure Test for ROM Featured at the Annual Meeting of the American College of Obstetricians and Gynecologists (ACOG)

A new, non-invasive test for ROM (Rupture Of (fetal) Membranes) in pregnant women, AmniSure™, was featured at the Annual Meeting of the American College of Obstetricians and Gynecologists in San Francisco, May 8-11 2005.

(PRWEB) May 15, 2022 -- A new, non-invasive test for ROM (Rupture Of (fetal) Membranes) in pregnant women that is both reliable and non–invasive was featured at the Annual Meeting of the American College of Obstetricians and Gynecologists in San Francisco, May 8-11 2005.


AmniSure™ is the first FDA approved ROM immunoassay. AmniSure detects Placental Alpha Microglobulin-1 (PAMG-1), a protein that is abundant in amniotic fluid. Eliminating the need for nitrazine, ferning and a speculum exam, AmniSure™ simply involves collecting a sample with a sterile swab, inserted only 2-3 inches into the vagina for one minute, then placing the swab into a vial with a solvent for one minute, followed by dipping an AmniSure™ test strip into the vial. The test result is indicated visually over the next 5-10 minutes by the presence of one or two lines. AmniSure is highly specific; semen, urine and vaginal infections do not interfere with the efficacy of the test. Clinical studies and additional information about AmniSure is available at: http://www.sepalsolutions.com

Sepal Reproductive Devices is a distinguished leader in the design, discovery and marketing of innovative medical products. Sepal supplies a full range of devices for assisted reproductive technologies as well as the latest advances in diagnostic testing devices that promote the health and well-being of women. Sepal’s range of testing kits includes ovulation and menopause detection kits, and a rapid diagnostic test that detects rupture of (fetal) membranes (ROM). Sepal is a privately held company based in Sudbury, Massachusetts. Since its inception in 2000, Sepal has serviced hundreds of healthcare professionals, infertility centers and hospitals around the world. We continue to expand our product line and reinforce our commitment to becoming the vanguard of women’s healthcare by bringing the most advanced technologies and devices to the medical industry. For additional information please visit: http://www.sepalreprodevices.com.

Posted by Industrial-Manufacturing at 11:34 PM | Comments (0)

May 13, 2022

tebu-bio to Distribute Covalys' SNAP-tag Products for Protein Labeling in Europe

Covalys and tebu-bio today announced that they have entered into an agreement under which tebu-bio will be Covalys' exclusive European distributor.

Witterswil, Switzerland and Le Perray, France (PRWEB via PR Web Direct) May 12, 2022 -- Covalys and tebu-bio today announced that they have entered into an agreement under which tebu-bio will be Covalys' exclusive European distributor. By adding Covalys' intracellular and in-vitro protein labeling kits to their offering, the agreement strengthens tebu-bio's position as a comprehensive pan-European provider of cutting-edge consumables for Life Science research.


Covalys' products allow rapid specific labeling of proteins inside live cells and in complex mixtures with a variety of fluorophores and affinity labels. These products are based on the proprietary self-labeling SNAP-tag technology and are provided under an open access license allowing for commercial use of the kits, including fee-for-service applications. The SNAP-tag technology is therefore an attractive alternative to fluorescent proteins for cell imaging studies, and will expand the tools available to biologists to study protein function and interactions.

Under the agreement, tebu-bio is the exclusive distributor of Covalys' product offering in Germany, France, UK, Italy, Spain, the Netherlands, Belgium, Luxembourg, and Scandinavian countries. Among the high-profile research products tebu-bio already has in its catalogue are Genospectra's Parallel Quantitative Biology (PQB) technologies and Quantum Dots novel solutions for biomolecular detection.

"We are extremely happy to have tebu-bio as a partner in Europe," said Christoph Bieri, Covalys' CEO. "tebu-bio is the only European distributor of life science reagents which is present in all major countries. This will give all scientists in this area immediate access to customer support in their native language. There is a nice fit of the SNAP-tag technology with tebu-bio's existing portfolio, and we are convinced they will make a great job of promoting and distributing our products."

"tebu-bio is very pleased to be selling Covalys SNAP-tag reagents," said Donald van Dijk, CEO of tebu-bio. "We are continuously looking for innovations and partnerships, and only ever consider the very best that can benefit our customers. Covalys versatile technology has been highlighted in Nature's 'Hottest Technologies of 2004,' and will allow us to continue to offer superior labeling technologies to our European customers."

About Covalys Biosciences AG:
Covalys provides products that help researchers in academic institutions and pharmaceutical and biotech companies to improve the efficiency of research into proteins and their function. Its SNAP-tag technology is the first commercially available protein tag which covalently links itself to any chemical probe provided as a substrate. Covalys' technology is exclusively licensed from the Swiss federal Institute of Technology Lausanne (EPFL). Founded in June 2002, Covalys has its headquarters in Witterswil near Basel, Switzerland. For more information, visit Covalys' website: www.covalys.com

About tebu-bio:
tebu-bio is specialized in reagents for research and custom services in the field of life sciences. Our goal is to help scientists from academic and private laboratories succeed in their daily work by providing innovative tools adapted to their needs. This is possible thanks to outstanding support from a qualified sales force and a team of scientists for advice, and efficient logistic service for optimised delivery. For more information, visit tebu-bio website: www.tebu-bio.com

Trademarks: SNAP-tagTM is a registered trademark of Covalys Biosciences AG.

Media Contact:
Tom Gibbs
Covalys Biosciences AG
Phone +41 (0)61 725 20 60
e-mail protected from spam bots

Media Contact:
Didier Lecommandeur
tebu-bio
Phone +33 (0)1 30 46 39 10
e-mail protected from spam bots

Posted by Industrial-Manufacturing at 06:22 AM | Comments (0)

May 12, 2022

Goodbye Harsh Sinus Medications: Florida Medical Doctor Invents a Natural & Gentle Nasal Spray to Relieve Sinus Problems and Nasal Congestion

SinusMagic nasal spray helps soothe your nose by moisturizing it and cleaning out the phlegm that may be mixed with pollutants like pollen, dust and smog, which are the main causes of many sinus problems. Reputable studies conducted by Dr. Rasoul Salman show that SinusMagic not only improves nasal symptoms but also decreases the incidents of nasal bleeding and infection.

Apalachicola, FL (PRWEB) May 12, 2022 -- Dr. Rasoul Salman has suffered from sinus problems all his life and was very frustrated by the side effects he experienced from nasal decongestants. To combat side effects, Dr. Salman made it his life’s mission to develop a natural sinus medication that would relieve his sinus congestion while being gentle on his nose. After many years of hard work and dedicated research, Dr. Salman developed SinusMagic.


SinusMagic is a gentle nasal spray helps soothe your nose by moisturizing it and cleaning out the phlegm that may be mixed with pollutants like pollen, dust and smog, which are the main causes of many sinus problems. Reputable studies conducted by Dr. Rasoul Salman show that SinusMagic not only improves nasal symptoms but also decreases the incidents of nasal bleeding and infection.

According to Dr. Rasoul Salman, "I am one of millions frustrated by sinus trouble. I have tried over the counter decongestants such as Afrin, Sudafed and other cold and sinus medications. All of the decongestants had side effects such as increased blood pressure, heart irregularity, nasal dryness and nasal bleeding. I also tried prescription nasal drugs (nasal steroids) such as Nasacort, Rhinocort and Flonase. The prescription steroids also had side effects such as loss of smell, viral, bacterial and fungal infections. I even tried surgery, which again did not help. It has taken me many years to develop a natural nasal spray that is gentle and works. I hope SinusMagic helps you as it has helped me and others."

SinusMagic Ingredients include: Salt and Water, Mucosolvin, Zinc Sulfate, Alum, Tolo Balsam, Tea tree oil, Glycerin, and Winter Green Oil (Methyl Salicylate).

For more information on SinusMagic Nasal Spray including research studies, an electronic brochure and product photos, please visit www.sinusmagic.com.

Media kits, high-resolution photography and product review samples are available on request.

Posted by Industrial-Manufacturing at 04:35 AM | Comments (0)

Baxa Corporation Named Finalist in 2005 American Business Awards

Baxa Corporation has been selected as a finalist in the Best Sales Team category for the third annual American Business Awards. Hailed as “the business world’s own Oscars” by the New York Post (September 22, 2021), The American Business Awards are the first national, all-encompassing business awards program honoring great performances in the workplace. Baxa was nominated for Best Sales Team in a submission reflecting how their entire company rallied to support customers during a critical product shortage.

Englewood, CO (PRWEB) May 12, 2022 -- Baxa Corporation has been selected as a finalist in the Best Sales Team category for the third annual American Business Awards. Hailed as “the business world’s own Oscars” by the New York Post (September 22, 2021), The American Business Awards are the first national, all-encompassing business awards program honoring great performances in the workplace. Baxa was nominated for Best Sales Team in a submission reflecting how their entire company rallied to support customers during a critical product shortage.


The 2005 Stevie Awards will be chosen from among the more than 1,200 nominations submitted for consideration. Nicknamed the SteviesTM for the Greek word “crowned,” winners will be announced during presentations on Monday, June 6 at the Marriott Marquis Hotel in New York City. During the ceremonies, which will be videocast on the Internet and broadcast on the radio, Donald J. Trump will receive the first Lifetime Achievement Stevie Award.

Finalists were selected by business professionals nationwide during three months of preliminary judging and represent more than 40 categories, including Best Overall Company, Best Executive, Best Corporate Social Responsibility Program, and Best Human Resources Organization. Members of the Awards' Board of Distinguished Judges & Advisors and their staffs will select Stevie winners from among the finalists. A complete list of finalists is available at http://www.stevieawards.com/aba/.

“We are honored by the recognition that this achievement represents for Baxa as a company,” noted Claude Hooton, Executive Vice President of Sales and Marketing for Baxa. "Although 2005 was a record year for the company in terms of financial growth, the real test of our performance is measured with long-term customer satisfaction. We can only do this with an effective sales team encompassing every member of Baxa from the sales person to the line associate building the product. This is truly a tribute to the great work of every associate at the company."

Baxa Corporation sells systems worldwide that are used for streamlining pharmacy compounding processes. In the US, UK, Canada and Germany, the company uses a direct sales force supplemented by an inside sales team. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Further information is available at http://www.baxa.com.

About The Stevie Awards
Stevie Awards are conferred in three programs: The American Business Awards, The International Business Awards, and The Stevie Awards for Women Entrepreneurs. Honoring companies of all types and sizes and the people behind them, the Stevies recognize outstanding workplace performance around the world. Learn more about The Stevie Awards at http://www.stevieawards.com. Premier sponsors of The 3rd Annual American Business Awards include Rogen International, ValueVision Associates, Veritude, Ultimate Software and The Professional Society for Sales & Marketing Training. Media sponsors include the Business TalkRadio Network, Hoover's Online, Selling Power Magazine and Wired Magazine. Speedera Networks will videocast the awards ceremonies live on the Internet.

Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 04:35 AM | Comments (0)

Nattokinase The “Japanese Wonder” Gets Your Blood Pumping

The Japanese live longer than us and have fewer problems with cardiovascular disease. Their excellent track record for heart health and longevity is partly due to their consumption of fish and seafood, but their overall well-being can also be attributed to something that is little known here in the West. What are they doing that we aren’t? The secret may lie in a unique discovery found in a naturally-occurring substance called natto.

(PRWEB) May 12, 2022 -- The Japanese live longer than us and have fewer problems with cardiovascular disease. Their excellent track record for heart health and longevity is partly due to their consumption of fish and seafood, but their overall well-being can also be attributed to something that is little known here in the West. What are they doing that we aren’t? The secret may lie in a unique discovery found in a naturally-occurring substance called natto.

Natto, sometimes called “vegetable cheese,” is made from fermented soybeans. According to Japanese folklore, ancient Samurai warriors not only consumed natto on a daily basis, they also fed it to their horses to increase their speed and strength. Natto has been used for over a thousand years in Japan as a folk remedy for fatigue, dysentery, heart, and vascular diseases. Natto enjoys widespread usage in Japan where the annual consumption is roughly four and a half pounds per person.

In 1980, Dr. Hiroyuki Sumi at the University of Chicago Medical School tested 173 foods for their ability to promote healthy circulation. He discovered a specialized enzyme found locked inside natto. This enzyme,dubbed “nattokinase,” did the job better than any of the other substances he was testing. Nattokinase is emerging as one of the most exciting and significant new breakthroughs in recent memory.

Dr. Sumi found that nattokinase had the ability to not only prevent clots from forming, but also dissolve clots that had already formed. Natto reduces the level of fibrin (the protein that accumulates inside blood vessels and eventually clogs them), and helps restore healthy circulation to diseased blood vessels. Until the discovery of nattokinase, we really didn’t have any natural solution to remove blood clots and dissolve fibrin.

Currently, nattokinase is best found in NSK-SD, which is an identical strain to that of Dr. Sumi’s original nattokinase. It is the only nattokinase that has actually been used in a U.S. hospital and is currently completing double-blind clinical trials in the U.S. and a 100 patient clinical trial with complete bloodcounts and metabolic panels.

“As a pharmacist and a naturopathic doctor, I consider the discovery of nattokinase to be a major discovery for those concerned with cardiovascular health issues and general overall health,” says Dave Foreman, known popularly for his nationally-syndicated radio show, The Herbal Pharmacist. “If you look at the physiology of the body and understand how nattokinase works, you can easily understand why this may be a supplement even the healthiest of people would want to use.”

One way to get a good dose of nattokinase is to eat natto in its traditional form. Unfortunately, its taste and odor is not particularly pleasing to the Western palette. A much better option is to take nattokinase NSK-SD in the form of dietary supplements.

“With the sound science behind nattokinase, I get peace of mind knowing that I am doing something proactive to help my health,” says Foreman whose family has a history of cardiovascular disease. “I regularly recommend nattokinase NSK-SD to those with any kind of circulatory issue.” Nattokinase NSK-SD is truly an economical way to clean your arteries. It’s shown to be safe, effective, and has no known side effects.

A healthy circular system is critical for a healthy heart and over all good health. If your circulatory system is functioning on an optimal level, it has profoundly positive effects throughout your entire body. Taking nattokinase NSK-SD in supplement form is by far one of the easiest things you can do to stave off the #1 cause of death and disability in this country.

For more information, please contact Jay Wilke at 727-443-7115, ext. 223.

Samples and photos available.

Posted by Industrial-Manufacturing at 04:33 AM | Comments (0)

May 11, 2022

Biopheresis Technologies, Inc. Announces 6.5 Million Euro Financing from International Investors; Cancer Clinical Trial Planned for 2005

Biopheresis Technologies, Inc., a U.S. company currently developing a novel cancer treatment system, announced today a 6.5 million Euro Series A preferred stock financing with Scandinavian Life Science Venture (SLS), Stockholm and First Ventury, Heidelberg.

Cary, NC (PRWEB via PR Web Direct) May 11, 2022 -- Biopheresis Technologies, Inc., a U.S. company currently developing a novel cancer treatment system, announced today a 6.5 million Euro Series A preferred stock financing with Scandinavian Life Science Venture (SLS), Stockholm and First Ventury, Heidelberg. The Company completed a clinical trial in 2004 that demonstrated capability of its proprietary medical device to remove specific immune inhibitors from the blood of cancer patients. Proceeds from this financing will be used primarily to conduct further clinical trials to demonstrate the effect of the Company's therapy on tumor disease, patient safety and well-being.


George Rehm, Managing Partner of First Ventury, said, "The immunological and medical device based therapy of Biopheresis is a fundamental new approach to the treatment of cancer, and we believe this approach will provide a major improvement in cancer therapy."

Commenting on this significant financing milestone, Santo J. Costa, Chairman of Biopheresis, said, "This investment in Biopheresis by SLS and First Ventury, who are leading investors in new medical technologies, further validates the Company's technology and our approach to the treatment of cancers. These two exceptional investment partners have already made important contributions to the Company's development, and with their funding we now will be able to accelerate the development of this new cancer treatment system."

Jan Sundqvist, Senior Investment Director of Scandinavian Life Science Venture, further commented, "Our relationship with Biopheresis marks another investment by SLS in companies with promising new medical technologies. We are impressed that the Company has already developed its technology and is in the process of defining manufacturing processes for scale-up and clinical trials. We are looking forward to the rapid maturation of Biopheresis' technology through further clinical trials and introduction of the Company's treatment into the medical marketplace."

About Biopheresis Technologies, Inc.
The Company’s immunological therapeutic approach is based on data that specific inhibitors in the blood produced by cancer cells retard or prevent an otherwise normal immune system from recognizing and destroying tumor cells. These inhibitors have been shown to be soluble Tumor Necrosis Factor receptors ("sTNFRs") and to be overproduced in cancer patients. The Biopheresis technology removes these inhibiting sTNFRs, to allow the body’s own TNF mediated immune response to attack and destroy tumors.

The Company's therapy uses a medical device, an immuno-affinity column that specifically removes inhibiting sTNFRs from patients' blood. Filing is in process for a CE (Conformite Europeanee) Mark in Europe for this medical device and a controlled breast cancer treatment trial is expected to begin in Europe in autumn 2005. Biopheresis also plans further discussions with the FDA to begin the clinical and regulatory approval process in the United States.

The Company has a number of patents issued in the United States, Europe and other countries. Other patent applications are pending both internationally and in the US. Proceeds of this financing will be used to complete the CE Mark process, conduct follow-on clinical trials and develop the Company's infrastructure. Biopheresis' U.S. headquarters are in Cary, North Carolina and European headquarters are in Heidelberg, Germany.

About Scandinavian Life Science Venture
SLS Venture, a Scandinavian-based venture capital company, is one of the largest investment funds in Scandinavia in the life science sector with approximately 270 million Euros under management. The vision of SLS Venture is to become a leading life science investor with the aim of maximizing return on investment by supporting high-potential small and mid-sized life science companies with a unique combination of capital, industrial and financial expertise and networks.

About First Ventury
Since its founding in April 2000, First Ventury has become one of Germany's leading venture capital firms. First Ventury invests in innovative start-up and early stage high technology companies in Europe and North America that have the potential to become market leaders. The Company employs a consistent, well defined investment process from the initial investment through to exit. First Ventury's management team consists of investment professionals with many years of international operational and entrepreneurial experience. This team has access to an extensive international network of advisers who provide the Company with management and industry expertise throughout the entire investment process.

Posted by Industrial-Manufacturing at 05:15 AM | Comments (0)

May 10, 2022

Good Samaritan Hospital Joins Unprecedented National Campaign to Save 100,000 Lives Through Health Care Improvements

As part of its ongoing commitment to providing quality medical care, Good Samaritan Hospital has joined the Institute for Healthcare Improvement’s “100,000 Lives Campaign,” the first-ever national campaign to save 100,000 lives by implementing proven health care improvement techniques.

Suffern, NY (PRWEB via PR Web Direct) May 9, 2022 -- As part of its ongoing commitment to providing quality medical care, Good Samaritan Hospital has joined the Institute for Healthcare Improvement’s “100,000 Lives Campaign,” the first-ever national campaign to save 100,000 lives by implementing proven health care improvement techniques. Good Samaritan Hospital was one of the first New York State hospitals to join this initiative, which has already enlisted more than 2,000 additional hospitals across the country.


The campaign was formally unveiled on December 14, 2021 and has been endorsed by such distinguished health care organizations as the American Medical Association, the American Nurses Association, the Centers for Medicare & Medicaid Services, the Joint Commission on Accreditation of Healthcare Organizations, and the Hospital Association of New York State (HANYS).

“Quality is the focus of everything we do at Good Samaritan Hospital,” commented Michael Schnieders, Executive Vice President and Administrator for Good Samaritan Hospital. “We are continually seeking new ways of doing things to elevate the quality of care that we provide to our patients and their families. We are proud to have joined with the Institute for Healthcare Improvement and hospitals nationwide in this historic effort to save 100,000 lives.”

Health care facilities that choose to participate in the Institute for Healthcare Improvement’s campaign commit to implement some or all of the following six quality improvement changes:

- Deploy rapid response teams that allow any staff member, regardless of position in the chain of command, to call upon a specialty team to examine a patient at the first sign of decline.
- Deliver reliable evidence-based care for acute myocardial infarction by consistently delivering key measures that prevent patient deaths from heart attack, including early administration of aspirin and beta-blockers.
- Prevent adverse drug events by implementing medication reconciliation, which requires that a list of all of a patient’s medications (even for unrelated illnesses) be compiled and reconciled to ensure that the patient is given (or prescribed) the right medications at the correct dosages - at admission, discharge and before being transferred to another care unit.
- Prevent central line infections by consistently delivering five interdependent, scientifically grounded steps collectively called the “Central Line Bundle.”
- Prevent surgical site infections by reliably delivering the correct perioperative antibiotics, maintaining glucose levels and avoiding shaving hair at the surgical site.
- Prevent ventilator-associated pneumonia by implementing five interdependent, scientifically grounded steps collectively called the “Ventilator Bundle” – such as elevating the head of the hospital bed by 30 degrees – thereby dramatically reducing mortality and length of stay in the Intensive Care Unit.

Good Samaritan Hospital has already taken steps toward all of the campaign’s health improvement changes by implementing procedures to help prevent deaths from heart attacks, adverse drug events, central line infections, surgical site infections and ventilator-associated pneumonia, and has formed rapid response teams, as called for in the campaign’s guidelines. Good Samaritan will look to expand upon those efforts in the months ahead.

“Good Samaritan Hospital sees this campaign as complimenting the quality and safety processes and goals that we currently employ,” stated Dr. James Luciano, Vice President for Medical Affairs. “Improving the care we give to patients is the number one priority of everyone who works at Good Samaritan. Focused efforts like this campaign have been shown to improve patient care. For those reasons, we are pleased to participate in the 100,000 Lives initiative.”

HANYS President Daniel Sisto held a news conference in Albany on Monday, May 9, to announce that well over half of New York's hospitals have voluntarily joined the 100,000 Lives Campaign. The HANYS Board of Trustees has endorsed the 100,000 Lives Campaign and continues to encourage all hospitals to sign up for one or more of the Campaign's six quality practice strategies. HANYS is the statewide coordinator for the IHI initiative.

Additional partners in the Campaign include the six regional hospital associations, the State Department of Health, Center for Medical Consumers, Medical Society of the State of New York, New York Organization of Nurse Executives, New York State Nurses Association, Health Plan Association of New York State, Business Council of New York State, IPRO, Healthcare Trustees of New York State, and United Hospital Fund.

“We are organizing a world-class campaign to elect quality,” said Dr. Donald Berwick, President and CEO of the Institute for Healthcare Improvement (IHI). “The health care organizations that join this campaign are not only demonstrating their commitment to improvement but their determination to put proven, life-saving improvement techniques into action.”

Good Samaritan Hospital is a member of Bon Secours Health System, Inc., one of the nation’s leading Catholic healthcare systems. It is also part of the regional Bon Secours Charity Health System, which includes St. Anthony Community Hospital in Warwick, NY and Bon Secours Community Hospital in Port Jervis, New York. Additionally, Bon Secours Charity Health System provides the services of a Certified Home Health Agency, two long-term care facilities, an assisted living and adult home facility and several other medical programs. For more information about Good Samaritan Hospital, or any of its programs, visit their website at www.goodsamhosp.org, or contact Good Samaritan Hospital at 845-368-5000.

Media Contacts:
John Lonsdorf
R&J; Public Relations
908-722-5757
e-mail protected from spam bots

Deborah Marshall
Good Samaritan Hospital
(845) 368-5570
e-mail protected from spam bots

Posted by Industrial-Manufacturing at 04:02 AM | Comments (0)

May 06, 2022

FlexLink AB Acquired by ABN AMRO Capital

FlexLink AB, a global leader in factory automation systems for the fast moving consumer goods, pharmaceutical, automotive, electronics and telecom sectors, announces its acquisition by ABN AMRO Capital, one of Europe's leading private equity providers.

Göteborg, Sweden (PRWEB) May 6, 2022 -- FlexLink AB, a global leader in factory automation systems for the fast moving consumer goods, pharmaceutical, automotive, electronics and telecom sectors, announces its acquisition by ABN AMRO Capital, one of Europe's leading private equity providers. FlexLink was acquired via a management buy-out from EQT, the private equity funds group that had originally acquired a 90% interest in FlexLink from AB SKF in 1997.

Under EQT’s ownership, FlexLink underwent comprehensive development, which resulted in FlexLink becoming a leading supplier of industrial automation equipment to production facilities in the global manufacturing and assembly industry. FlexLink today has a large and well-diversified customer base and has developed from a supplier of components to offering complete automation solutions for production processes.

FlexLink, founded in 1980, has 540 employees, with head office in Göteborg and business activities in 50 countries, including its own sales offices in 21 countries. In 2004 FlexLink achieved EBITDA of EUR 18 million in 2004 on turnover of EUR 125 million.

Johan Bjurström, Nordic Head of ABN AMRO Capital, said the company had prospered under its previous ownership but had further potential for geographic growth and to lead consolidation in its sector - key investment criteria for ABN AMRO Capital. "FlexLink is well positioned for future growth, as factory automation systems continue to develop in sophistication in response to the increased use of robotics and the growing need for flexibility in manufacturing," he said.

Fredrik Jönsson, FlexLink’s CEO, stated, "After FlexLink’s strong development during EQT’s time as an owner, I am convinced that with ABN AMRO Capital as new owners we will have the best possible preconditions to continue our growth during the coming years. We have built a platform for continued strong growth consisting of a leading range of products for the global market."

ABN AMRO Capital is the global private equity business of ABN AMRO, with teams operating in 10 countries worldwide including the Netherlands, UK, France, Spain, Italy, Sweden and Australia.

Netherlands-based ABN AMRO is a leading international bank with total assets of EUR 608.6 bln (as at 31 December 2021). It has over 3,000 branches in more than 60 countries and territories, and has a staff of about 100,000 full-time equivalents worldwide. ABN AMRO is listed on the Euronext and New York stock exchanges.

EQT is a group of private equity funds that manages just below EUR 6 billion in equity in 7 funds. EQT Partners, acting as investment advisor to all EQT funds, has offices in Stockholm, Copenhagen, Helsinki, Frankfurt and Munich. In total EQT has invested in 37 companies, with a combined enterprise value of approximately EUR 13 billion.

For more information, visit www.flexlink.com; or contact Mats Nilsson, Corporate Communications, Tel. +46-(0)31-337 12 20, E-mail: e-mail protected from spam bots. In the United States, contact Paul Jarossy, Marketing Manager, at FlexLink Systems, 6580 Snowdrift Road. Allentown, PA 18106, tel. +1.610.973-8200, fax +1.610.973-8345.

Posted by Industrial-Manufacturing at 03:05 AM | Comments (0)

NephroGenex Licenses Molecular Profiling Technology and Kinase Inhibitors for Kidney Disease

Cary, NC (PRWEB via PR Web Direct) May 5, 2022 -- NephroGenex, Inc., a biotechnology company developing treatments for kidney disease based on molecular profiling, announced today the signing of two licensing agreements that provide the company with a kidney-specific molecular profiling technology and inhibitors of a novel kinase therapeutic target for renal disease.

NephroGenex has acquired exclusive commercial rights to the glomerular transcriptome profiling technology developed by Drs. Karl Tryggvason and Christer Betsholtz of the Department of Medical Biochemistry and Biophysics at the world renowned Karolinska Institute in Stockholm, Sweden. This technology utilizes "GlomChip," a DNA chip developed to measure expressed genes in the glomerulus. The glomerulus is the filtration unit of the kidney and the micro-organ where the leading renal diseases originate and progress. Glomchip measures the expression of over 6000 genes, 300 of which are only expressed in the glomerulus, and not other parts of the kidney. This molecular profiling technology is being used to identify key renal-specific pathogenic pathways that emerge in the leading kidney diseases.

Current treatments for the leading renal diseases target causative systemic pathologies (e.g. blood pressure, immunological response). These treatments are at best marginally effective, and do not appreciably delay the progression to end stage renal disease (ESRD). The prevalence and incidence of ESRD continues to rise. Targeting renal-specific pathology has shown promise in preclinical studies. However, the diversity of disease processes that are activated in the kidney due to diabetes, hypertension, circulating IgA and lupus (i.e. the leading renal diseases), has hampered drug development efforts.

"This kidney-specific molecular profiling technology represents a fundamental component of our approach to characterize the complex pathology of renal disease," indicated Dr. Wesley Fox, President and CEO of NephroGenex. "This technology will enable NephroGenex to utilize established clinical candidates that target renal-specific disease pathology and direct them to patients that are more likely to respond to the action of the drug."

NephroGenex has also acquired exclusive commercial rights in the renal disease field to a proprietary GPBP kinase technology and inhibitors being developed in the laboratory of Dr. Juan Saus at the Fundacion Valenciana de Investigaciones Biomedicas (Biomedical Research Foundation), Valencia, Spain. GPBP (Goodpasture antigen binding protein) kinase is active against extracellular matrix molecules, and appears to play an important role in their proper organization and function. According to Dr. Fox, "Elevated expression of GPBP kinase has been shown to accompany inflammatory and fibrotic disease processes, and GPBP kinase inhibitors dramatically reduce glomerulosclerosis and lung fibrosis in preclinical studies."

About NephroGenex, Inc.
NephroGenex is a new biotechnology company developing treatments for kidney disease utilizing the latest scientific advancements in molecular profiling. More than 20 million Americans have some form of chronic kidney disease, and over 400,000 in the US have end stage renal disease (ESRD), making renal disease one of the costliest illnesses to treat. Kidney disease is a very complex disease, and although a number of preclinical drug candidates have been identified in the last decade, few clinical trials have been initiated.

NephroGenex's kidney-specific, glomerular molecular profiling technology is establishing molecular profiles or "fingerprints" for the leading renal diseases. These profiles provide for the identification of disease pathways that are active in a patient's renal disease. In addition, the incorporation of molecular profiling into Phase II clinical trials provides for the determination of profiles and/or biomarkers that identify patients that respond to the drug candidate under evaluation. These identified profiles and biomarkers can subsequently be incorporated into pivotal Phase III trials, increasing the likelihood of demonstrating a statistically significant treatment effect. Moreover, molecular profiling has the potential to significantly reduce the size, length and cost of clinical trials.

The founders and collaborating scientists of NephroGenex are world leading experts on the molecular basis of kidney disease and the application of genomic and proteomic molecular profiling to the characterization of glomerular disease processes.

Contact:
J. Wesley Fox, Ph.D.
President and CEO
NephroGenex, Inc.
(919) 678-9512
www.nephrogenex.com
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 03:04 AM | Comments (0)

May 05, 2022

Research and Markets: Steady Growth in BRIC Markets Forecast to Erode Commercial Differences with Established Markets of North America, Japan and Europe

PRWEB) May 5, 2022 -- (http://www.researchandmarkets.com/reports/c16829) has announced the addition of The Market for Medical Devices & Equipment in Brazil, Russia, India & China to their offering

For years the huge markets of Brazil, Russia, India and China (the BRIC economies) have promised much and delivered little. Ongoing political and economic issues have held them back from realising their true potential in the global market. But is all that set to change. These markets have endless potential, considering that in less than 40 years time, the BRIC economies together could be larger than the G6 in US dollar terms, in US dollar terms, China could overtake Germany in the next four years, Japan by 2015 and the US by 2039!

This is evolution not revolution, and change will be progressive. Common characteristics to be found among the four markets include low levels of health expenditure, wide unmet clinical and social need and variable health provision. The real opportunities lay in the future, where steady growth in BRIC markets will erode the commercial differences with the established markets of North America, Japan and Europe.

Effective planning is vital, and impartial, thoroughly researched information is essential to fully appreciate the current status as a basis for future development. The Market for Medical Devices & Equipment in Brazil, Russia, India & China. In addition to highly detailed chapters on each market, this report provides a thought-provoking and comparative examination of the BRIC economies, putting opportunities into their current and future context.

Following a comparative overview, the report provides details for each country on the following areas:
- Medical Device Market Outlook
- Background Data
- Healthcare System
- Accessing The Pharmaceutical Market
- Contact Details

For more information visit http://www.researchandmarkets.com/reports/c16829

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980

Posted by Industrial-Manufacturing at 04:34 AM | Comments (0)

May 04, 2022

Canadian Pharmacy Still Helping Americans Save on Prescriptions

Canadian Pharmacies can save customers money by providing safe, approved, and affordable medicine that is identical to what you would receive from a U.S. based Drugstore.

(PRWEB) April 25, 2022 -- With the rising cost of medicine and the cuts to senior health care, many people are wondering, "where can we save money on our prescriptions"? We hear about it in the media, on talk shows, and even in Congress.


There are many ways to save on medicine but there is always the concern that ordering prescription drugs over the internet is not safe or the online Phramacy does not even exist.

The concerns most people have is...
- not receiving any item at all.
- not receiving the same identical product.
- receiving a lesser generic or not the equivalent strenght or dosage ordered.
- poor customer service if any at all.

Yes this does happen but the good thing is, most online companies are legit.

What you should look for on the website are the following:
- a 1 800 toll free telephone number and operators that actually answer the phone
- a physical address, a place that you could go and open a door and talk to someone if needed.
- make sure that the pharmacy is approved by the governing body of pharmacies of where that pharmacy is located.
- a website that appears honest, answers all your questions, and is secure for online shopping and privacy.
- and most of all, use your common sense. Pick up the phone if you are unsure and call them up. Ask them questions, before you order.

So have much money can you save? Take Tamoxifen for example. Drugstore.com – the biggest online drugstore in the U.S. – sells 100 of the breast cancer treatment tablets for $77.77 US. That very same order retails for $42.00 from British Columbia based company www.77canadapharmacy.com/tamoxifen – an astonishing difference that's making more and more Americans take notice.

A customer can choose from Brand name Medicine, or can choose less expensive Generic medicine that is identical to the major manufacturers but can save you up to 77% off the Brand Name Prescription.

Help your friends and family save on medicine from an approved friendly Canadian Pharmacy come visit us at: www.77canadapharmacy.com

Posted by Industrial-Manufacturing at 11:24 PM | Comments (0)

World’s First Hot Pepper Nasal Spray Moves into Canadian Retail

Sinus Buster hot pepper nasal spray has become perhaps the “hottest” natural health product ever. Known as the world’s first hot pepper nasal spray, Sinus Buster has grabbed worldwide attention from medical researchers, doctors and thousands of patients suffering from chronic sinus, headache and allergy conditions. Growing demand north of the American border has prompted SiCap Industries (makers of Sinus Buster) to initiate a retail rollout to stores throughout Canada.

Albany, NY (PRWEB) May 4, 2022 -- Sinus Buster hot pepper nasal spray has become perhaps the “Hottest” natural health product ever -- in more ways than one. Known as the world’s first hot pepper nasal spray, Sinus Buster has grabbed worldwide attention from medical researchers, doctors and thousands of patients suffering from chronic sinus, headache and allergy conditions. Growing demand north of the American border has prompted SiCap Industries (makers of Sinus Buster) to initiate a retail rollout to stores throughout Canada.

“It’s about time we did it. We’re in hundreds of small stores. Most of them in America and some overseas, but nothing in Canada until now. We have so many internet customers from Canada that beg us to get Sinus Buster in stores up there. Canadians complain how the mail system and customs can be pretty slow getting it there and sometimes it just doesn’t make it at all. It'll be so much more convenient for these customers to get their Sinus Buster in local Canadian stores,” says Wayne Perry, president of SiCap Industries.

SiCap had a tough time choosing a distributor for Canada because things above the American border are quite different when it comes to selling natural health products. The Canadian government has far stricter rules for dietary supplements than those of the United States. According to SiCap’s management team, they were holding out for a distributor that not only understood the rules, but also believed in the product.

SiCap Industries recently signed a distribution deal with S&D; Enterprises of Alberta. This deal entitles S&D; to exclusive distribution rights throughout Canada. That includes retailers (large and small) in every province. S&D; will also be launching a website catering to Canada’s online shoppers at (www.sinusbuster.ca) in the coming months.

“We’ve been approached by a bunch of distributors in Canada, but S&D; had the right stuff. I mean they really got the concept of Sinus Buster. They’ve used it and they believe in it, and they understand Canadian law as it relates to natural health supplements. This is a very tough product to promote if you haven’t tried it because everything you read about it seems like pure hype, but it really does work for almost everyone. This stuff puts mainstream headache medicines and sinus sprays to shame. And believe me Sinus Buster lives up to and beyond its' reputation,” adds Perry.

In America, Sinus Buster has become an underground star of the headache and sinus world. Not only does it have a solid reputation for relieving the worst chronic sinus and headache symptoms, but it's also known for promoting healthy sinuses as a dietary supplement. Sinus Buster has received top notch reviews in the Wall Street Journal, Reader’s Digest UK, Prevention Magazine and numerous NBC, ABC and FOX television news affiliates.

In Canada, Sinus Buster will be marketed with a little less zeal than in the United States, but nonetheless the message will be the same. Sinus Buster has shown itself to be highly effective for relieving a multitude of sinus and headache symptoms for thousands of users. In addition, there are a handful of clinical studies showing Capsaicin, (the active ingredient in hot peppers & Sinus Buster) to be a potential remedy for chronic headaches and a wide variety of conditions involving sick sinuses.

Thus far, Sinus Buster has shown that it may be effective on both bacterial and allergic sinus conditions for a large number of sufferers. Of course this is based largely on anecdotal evidence presented by verifiable patients and physicians, but the testimonials are nonetheless compelling. Sinus Buster has also built a substantial following by the medical research community. There are presently two European clinical trials underway, and two other American trials planned for the coming fall.

The European trials are looking at chronic sinus conditions in one group and (believe it or not), the potential weight loss benefits of intranasal capsaicin in another group. Dozens of positive studies have been done with synthesized Capsaicin, but nothing has appeared to have such notable success rates as the Sinus Buster formula. Therefore researchers are looking specifically at the Sinus Buster formula as opposed to general capsaicin applications based on preliminary studies showing this formula to be more effective than anything synthesized in a lab.

"You have to understand that it’s not just the capsaicin that’s helping these people. It’s the way we’ve combined it with other herbals and the fact that we use natural extracts. This formula is a trade secret that cannot be exactly duplicated, and researchers are beginning to believe our company stumbled onto something that’s medically spectacular. Lets face it, Sinus Buster has been around for more than a year now and we've had tens of thousands of users who consider it almost miraculous,” says Perry.

When the American study launches in a few months, Perry says researchers will concentrate on two groups – one with Allergic Rhinitis and the other with Nasal Polyps. Although the reputation of Sinus Buster is a solid one, these clinical trials are an important step for mainstreaming this emerging medical breakthrough.

“We have hundreds of physicians recommending Buster to their patients. We know it doesn’t work miracles for everyone, but really nothing does. Not even surgery, but I’ll tell you this….Sinus Buster shows more potential than anything else on the market. This formula will stop a migraine or any headache for that matter within minutes for at least 90% of users. And when it comes to sinus infections and allergies, nothing comes close to Sinus Buster. This is a truly all natural product that can do what mainstream cough and cold products can’t. And once the clinical trials are complete, science will back up what our thousands of anecdotal reports already show,” Perry brags.

According to spokespeople for S&D; Enterprises and SiCap Industries, Canadian retail interest in Sinus Buster has been brisk from the start with the first shipments being pre-sold to a number of stores. The launch has already begun in Alberta, and if all goes well Sinus Buster will be springing up on the shelves of retailers throughout Canada. Look for Sinus Buster to start hitting Canadian health food shops, supermarkets and pharmacies by the end of May.

To find out more about Sinus Buster hot pepper nasal spray in Canada, call 1-866-705-0680. The Canadian Sinus Buster website is also up and running (www.sinusbuster.ca) although it won’t be complete for several weeks.

All "Canadian Medical & Media” inquiries should be directed to S&D; Enterprises of Alberta at the contact information in the body of this release.

In addition, all "Non-Canadian Medical & Media" inquires should be directed to SiCap Industries in the United States via the contact information that accompanies this release.

Posted by Industrial-Manufacturing at 11:23 PM | Comments (0)

The Right Moves: New E-book Offers Program to Alleviate and Prevent Common Shoulder Pain

Respected physical therapist and top fitness professional, Brian Schiff, has created "The Ultimate Rotator Cuff Training Guide," an innovative and scientifically based e-book on managing shoulder pain and rotator cuff injuries. This comprehensive guide covers shoulder anatomy, common causes of injury, exercise modifications, illustrated examples of rotator cuff specific exercises and and a complete 6 week program for an inflamed rotator cuff.

(PRWEB) May 4, 2005-- For the 30 percent of Americans suffering from shoulder pain, the new e-book, “The Ultimate Rotator Cuff Training Guide” holds the answers to both alleviating common shoulder pain and preventing injuries.

Brian Schiff, a licensed physical therapist working in sports medicine and co-founder of Fitness Edge Performance, a performance enhancement company specializing in sport-specific training programs for athletes of all sports and ages, developed the book after working with hundreds of patients suffering from rotator cuff injuries to the shoulder, such as tendonitis, bursitis and tears. According to Schiff, injuries such as these may be caused by natural degeneration, trauma or overuse.

Until now, Schiff said, the average American has not had access to a comprehensive manual to teach them about proper exercise form and specific rotator cuff exercises to prevent such an injury. Schiff also mentioned that many people have shoulder pain, but are not aware that they have a rotator cuff injury.

“As a physical therapist and fitness trainer, I have seen hundreds of people being hindered by this type of problem. The good news is that this type of injury is preventable as it usually develops as a result of improper exercise techniques,” Schiff said. “I wanted to produce a resource that could guide people in both preventing the injuries and managing them once they occur.”

In addition to an overview of rotator cuff problems and how to detect signs of injuries, the book contains information on common mistakes and training pitfalls, detailed descriptions and pictures of rotator cuff strengthening exercises, and a step-by-step program to alleviate pain or prevent a possible injury. Schiff said he has worked with several clients who have been able to resume normal activities of daily living or their favorite sports as a result of the program.

Donna Newman was diagnosed with a left rotator cuff tear and tendonitis in both shoulders. After following the rotator cuff training program, Newman said she regained full motion, strength and use of her arms.

“Since I work as a dental hygienist,” said Newman, “this was critical in allowing me to work without limitation and pain.”

Not only is the book beneficial for individuals, Schiff noted, but serves as a guide to sports trainers in understanding the nature of many shoulder injuries and how best to prepare the body. Golf Fitness Trainer Susan Hill said she uses the book as her pocket guide to working with golfers.

“This book answers the majority of questions I get daily regarding what can be done, when to see a physician and what exercises will help in redeveloping strength and flexibility for athletes at all levels,” said Hill.

To order a copy of “The Ultimate Rotator Cuff Training Guide” or for more information, visit www.rotatorcufftraining.com. The e-book is being offered for a one-time fee of $29.95 and can be viewed with Adobe Reader. The e-book also comes with special bonus reports including “Osteoarthritis: Safe and Effective Exercises,” “How to Identify and Prevent a Herniated Disc,” and “A 60 Minute Interview with Brian Schiff.”

Brian Schiff, PT, CSCS, graduated from The Ohio State University in 1996 with a Bachelor of Science degree in Physical Therapy and has practiced as a licensed physical therapist specializing in sports medicine for nearly a decade. Through the National Strength and Conditioning Association, Brian became a certified strength and conditioning specialist (CSCS) in 1998. He is a founding member of The American Association of Personal Trainers and recently co-authored a breakthrough manual on ACL injury prevention entitled “Protecting the Athlete’s Knee”.

In addition, Schiff contributed to the fitness book, “The Power of Champions” and “The Fitness Secrets of Championship Golfers.” Schiff owns the private fitness studio, the Fitness Edge, and co-owns Fitness Edge Performance, a performance enhancement company specializing in sport-specific training programs for athletes of all sports and ages. Schiff presents at professional conferences and coaches’ clinics on topics including training for shoulder stability and sport-specific training. For more information on the Fitness Edge and Fitness Edge Performance, visit www.thefitnessedge.cc and www.fitnessedgeperformance.com.

Posted by Industrial-Manufacturing at 11:22 PM | Comments (0)

Altoona Hospital Chooses Renol to Improve Osmometer Accuracy - New Reference Material More Accurately Reflects Patient Samples

Advanced Instruments, Inc. (www.aicompanies.com) today announced that Altoona Hospital, Altoona, Pennsylvania, has selected its RenolTM urine reference control to calibrate the osmometer in its diagnostics laboratory. Osmometers are used by clinical laboratories to provide the fastest results in diagnosing drug intoxication, renal function, head trauma, and other applications.

Norwood, MA (PRWEB) May 4, 2022 -- Advanced Instruments, Inc. (http://www.aicompanies.com) today announced that Altoona Hospital, Altoona, Pennsylvania, has selected its RenolTM urine reference control to calibrate the osmometer in its diagnostics laboratory. Osmometers are used by clinical laboratories to provide the fastest results in diagnosing drug intoxication, renal function, head trauma, and other applications.


“When Advanced Instruments Renol urine control material became available, we tried it on our osmometer to determine if it would achieve better results,” said Doug Decker, assistant lab supervisor, Altoona Hospital. “In our trials, we've found that Renol's ranges are more in line with what we would find from our patient samples. The normal range of the constituents in human urine is very wide. And the Renol controls better reflect the normal ranges for osmolality that we expect to see in our patient population. The two are very close. This strong correlation is the main reason we will be switching to Renol. For our lab, it will result in more accurate performance of our osmometer,” he said.

Decker also said the while the lab’s quality control program is in compliance, the addition of Renol has enhanced their efforts. “If two control points are acceptable, then four are even better,” he said.

Renol is the world's only osmometer-specific control solution designed for laboratories testing urine samples.

“We received a lot of feedback that osmometer users were looking for a better material than the multi-analyte controls presently on the market,” said Ken Micciche, director of marketing, Advanced Instruments. “Our goal was to design a reference solution that goes beyond quality control compliance and helps laboratories such as Altoona Hospital's maximize the accuracy and precision of their instruments.”

Micciche explained that the wider tolerances in multi-analyte controls can mask variations in osmometer performance while still maintaining CLIA compliance.

“Let's say you want your instrument to perform as optimally as possible. If you use a multi-analyte control with a range of 40 (± 20), your osmometer might test at 35 today and at 8 tomorrow, you may feel secure that your instrument is operating within the claimed specifications of the control. But going from 35 to 8 is a significant swing in performance. On the other hand, if you are using Renol, with an expected range of ±10, you're getting much better control over what's going on. As you collect your data points, you want to observe good, day-to-day control without swings in osmometer performance. It is this capability to operate your machine to very tight control points that ensures the precision of the testing procedure being used,” he said.

Micciche said Renol offered additional benefits to the Altoona Hospital Lab. “While the material's chemical makeup simulates urine, it is not a biological fluid and is completely safe for laboratory personnel to handle,” said Micciche. The aqueous-based solution comes premixed and is ready-to-use. It does not require freezing for storage and it is very stable. Renol comes in formulation values of 300 and 800 mOsm/kg H2O. “These concentrations are very close to medical decision levels where performance is critical for the use and interpretation of the test,” he said.

About Altoona Hospital
Altoona Hospital is a 346-bed, non-profit regional medical center serving central Pennsylvania. The hospital provides the area with a wide variety of health services, including cardiac care and surgery, cancer treatment, kidney dialysis, pain management, behavioral health services, women's reproductive health, pediatrics, outpatient services, and a regional trauma center.

About Advanced Instruments
Founded in 1955, Advanced Instruments, Inc. is the world's largest supplier of freezing-point osmometers used in clinical, pharmaceutical, and biotechnology laboratories. The company is also a leading supplier of analytical instruments and test kits for the food, dairy, and industrial microbiology markets. Based in Norwood, Massachusetts, USA, the company also produces Fiske® Associates brand diagnostic instruments and operates Spiral Biotech, Inc., and Delta Instruments as wholly-owned subsidiaries. Advanced Instruments’ products are supported by a worldwide network of direct sales people and independent distributors. The company can be found online at http://www.aicompanies.com or contact customer service at 800-225-4034 or +1-781-320-9000.

Posted by Industrial-Manufacturing at 11:22 PM | Comments (0)

May 02, 2022

Baxa Corporation Introduces New PhaSeal® System Component For Accessing Needleless Connectors

Baxa Corporation announces the release of the new PhaSeal System Connector, which attaches a PhaSeal Injector to an IV line for safe administration of hazardous drugs. The new Luer Lock Connector was redesigned in response to customer requests for a closed system that can be used with needleless IV access devices. The new connector is longer, to accommodate valve-actuated access devices, while ensuring that the injector needle is never exposed.

Englewood, CO (PRWEB) May 2, 2022 -- Baxa Corporation announces the release of the new PhaSeal System Connector, which attaches a PhaSeal Injector to an IV line for safe administration of hazardous drugs. The new Luer Lock Connector was redesigned in response to customer requests for a closed system that can be used with needleless IV access devices. The new connector is longer, to accommodate valve-actuated access devices, while ensuring that the injector needle is never exposed.

The PhaSeal System is a set of disposable containment devices that connect the original drug vial, syringe and IV injection or infusion set together for a completely sealed drug pathway. The system’s double membrane provides dry connections between system components, preventing drug leakage. Because PhaSeal is a closed system, hazardous drugs are contained throughout the entire process of drug transfer, preparation, transport, administration and disposal. The new connector ensures that the PhaSeal System remains closed, even with unique valve-actuated IV line access devices.

“The PhaSeal System is the only documented, closed system for safe handling of antineoplastics and other hazardous drugs,” affirms Agneta Ekblad, RN, Vice President, Oncology Solutions for Baxa Corporation. Closed systems have been recommended by the National Institute for Occupational Safety and Health (NIOSH) and the Oncology Nurses Society to provide an engineering control against environmental and personal contamination. An Alert published by NIOSH in March 2004 details research describing the significant health risks related to handling, mixing and administering hazardous drugs. The document recommends a number of measures to reduce or eliminate human exposure to these toxic hazards in the workplace.

The new PhaSeal Connectors are currently in inventory, and replace the previously sold connectors. Products are available directly from Baxa Corporation and also through medical products wholesalers, under the original order numbers.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

About Carmel Pharma ab
The PhaSeal System is manufactured in Sweden by Carmel Pharma ab of Göteborg, Sweden. Introduced in Europe in 1994, the PhaSeal System is used in most Swedish hospitals, with its benefits documented by a significant body of scientific research on the health risks associated with the preparation and administration of cytotoxic drugs. The PhaSeal System is protected by a comprehensive patent portfolio in the U.S., European Union and Japan. For more information on Carmel Pharma, please visit http://www.carmelpharma.se.

Click the following link to view a presentation by Jim Jorgenson "Using a Closed System Device to Reduce Occupational Exposure to Hazardous Drugs." Jorgenson is Director of Pharmacy for the Huntsman Cancer Institute and Associate Dean for Professional Affairs at the University of Utah:

http://www.isips.org/presentations/PhaSeal/player.html

"What if the Cure is Also a Cause?
The Same Chemo Drugs That Save Some Cancer Patients' Lives Put Health Workers at Risk"
A Major Daily Newspaper Looks at this Issue in Depth: February 15, 2022
http://www.washingtonpost.com/wp-dyn/articles/A24458-2005Feb14.html?referrer=emailarticle

Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots

Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: e-mail protected from spam bots

Posted by Industrial-Manufacturing at 04:57 AM | Comments (0)

May 01, 2022

Theramedix Revitilizes Enzyme Industry - Launch to Healthcare Professional Market Just A Few Weeks Away

Here's the latest news in the enzyme industry! Theramedix is launching its new line of plant- based pharmaceutical-grade enzymes (available only to the professional health care practitioner market) in mid-May. The Theramedix debut will be at the ACAM conference in Orlando.

San Francisco, CA (PRWEB) May 1, 2022 -- One of the most promising product launches of the season is coming up this month at the ACAM’s 63rd International Educational Conference on Complementary, Alternative and Integrative Medicine in Orlando, Florida. The Theramedix premiere line of plant based pharmaceutical grade enzymes will be officially introduced and available to the healthcare practitioner market, nationwide. Theramedix is a subsidiary of Enzymedica, a company that has provided high potency enzymes to the retail market since 1998 and is marked by SPINS research as the top retail line nationwide. The Theramedix line is proven to be the highest potency brand and is not available over the counter. It is expected that practitioners will engage as full partners in the promotion and use of these products due to the integrity of the product-line and the exclusive Thera-blend ™ system for the top four categories of enzymes: protease, lipase, amylase and cellulase. Through Thera-blend technology, each of these categories is represented by multiple enzymes, guaranteeing higher activity and natural integrity as opposed to other brands in the HCP market.

“Enzymes can provide many health benefits, but the benefits are only as effective as the delivery system. Why formulate something that does not work optimally in the body?” said Kalyna Hanover, Director of Theramedix. “The Thera-blend technology is a true innovation in that it offers genuine functional benefits. Health care professionals no longer have to question whether a particular enzyme is working in various pH levels throughout the digestive system. We have optimized enzyme activity in a wider pH range, while continuing to focus on efficacy.“

“We are very excited to partner with health care professionals,” said, Tom Bohager, CEO of Theramedix. “They have come to the right place, because Theramedix’s entire focus and purpose is enzymes. We are the experts of our niche and this is a pure, highest potency, broad spectrum line of enzyme formulations, which has been missing from their healthcare practice.” Unlike most of their competitors, Theramedix does not make vitamin, herb or mineral supplements.

Theramedix, a subsidiary of Enzymedica, formulates a premiere line of plant based pharmaceutical grade enzymes to health care professionals. Theramedix offices are located in San Francisco, California and the distribution facility is in Venice, Florida.

Log onto www.theramedix.net. For media inquiries please contact Connie St. John at 415-454-2243 or connie "@" stjohnpr.com

Posted by Industrial-Manufacturing at 11:35 PM | Comments (0)

Healing Health Care

Healing Health Care: New Cures and Treatments As Billy nears the end of his forty-fifth year old age begins to shed its ominous light over every aspect of his life. He has already watch four of his teeth rot out because, although he works nea...

(PRWEB) May 1, 2022 -- As billy nears the end of his forty-fifth year old age begins to shed its ominous light over every aspect of his life. He has already watch four of his teeth rot out because, although he works nearly sixty hours a week, he cannot afford basic health care. As he enters the twilight years of his life, earlier than anyone should, he is faced with failing health and no way to pay the doctor bills. The fact that someone who has worked all their life may not be able to obtain adequate medical and dental care because of their station in life goes against all the ideals that have made America great.

As we enter into the twenty-first century we see new cures and treatments springing into our clinics and homes at an unprecedented rate. Only a fool would argue that these advances are not helping millions, but the costs inherent with these new remedies make them inaccessible to many Americans who would benefit greatly from them. From 1971 to 1991 the price of health related goods and services climbed 30 percent faster that of other goods, placing far out of the financial reach of the working class of this nation. It is time to consider a true national health-care system, in order to insure that everyone, not just the wealthy, can enjoy good health. As it stands, America is the only civilized country where access to basic health care depends on where one works and how much one is paid. For many well insured people there is debate about our nation's stance on the separation between the individual and the state, but the fact of the mater is that if our friend Grant had been born five hundred miles to the North he would still have his teeth and a much brighter future.

In Canada, where they have had a national health insurance since 1967, a citizen is guaranteed treatment for any illness that may afflict him or her. In addition to keeping their people heather, and as a result happier, the Canadian system has kept costs minimal while research and development has continued at the same, if not faster, pace that we see here. Around the globe we can see the correlation between national health care systems and better quality of treatment. In Japan, they have countered the medical problems inherent with a crowded society through national health insurance, and as a result enjoy a extremely high quality of living. Even here we have harnessed some of the power of collective medicine, through publicly funded institutions such as the Center for Disease Control and many smaller research projects. These projects, sponsored by state and federal, have yielded many important breakthroughs, yet many Americans cannot afford the technology that they helped to pay for.

And if we continue on the course we have set for ourselves, more people will become medical have-nots. The problem of skyrocketing health costs is already beginning to force many employers to drop many important health benefits from the insurance plans they offer new hires, locking many people into jobs they no longer want for fear of losing benefits. Many small businesses have been forced to stop offering health insurance all together because they cannot afford to pay the bills. The American Hospital Association concluded that between 1995 and 1996 twenty percent of American workers would lose their employment-based insurance, and ten percent of them would lose their retirement coverage. When we add those millions to the millions who never had any health insurance to begin with we can begin to grasp the magnitude of the problem that we must face.

We must also realize that those of us who know that if we became ill we would be cured can never fully comprehend what life would be like without that simple insurance. For the millions who cannot even afford to health care for themselves, let alone their families, the trouble is frighteningly real. And for the millions who are presently insured the problem is about to become much more real unless we act quickly. That even one person would have to be sick when they could be made well quite easily is a grave injustice, but that millions of hardworking Americans are robbed of proper health care makes a mockery of all of the principles that America has stood for. For a nation, our nation, to say that it stands for ?life, liberty, and the pursuit of happiness,? and then let its workers toil without hope of an end to their toil is idiotic. The question of national health care is really a test of America's intentions, of whether or not we are willing to sacrifice the good of the many for the good of the few. Let us choose to come together as a nation and beat this thing, so that we may continue to be the model of what a country can be, rather then what a country could have been.
for more info on better health, go to http://www.allyourpills.com.

Posted by Industrial-Manufacturing at 11:34 PM | Comments (0)

Begüm Tümer Joins Theramedix as Illinois Enzyme Consultant

Exciting news in the nutraceutical industry: Theramedix is gearing up for their launch by building their regional staff. This week, Begüm Tümer came on-board to serve the Illinois health care practitioner market.

San Francisco, CA (PRWEB) April 30, 2022 -- Theramedix, a nutraceutical company that provides health care practitioners with a plant based pharmaceutical-grade line of enzymes, announced today that Begüm Tümer has joined the Theramedix staff as their Illinois Account Executive and Enzyme Consultant. Theramedix is a subsidiary of Enzymedica, a company that has provided high potency enzymes to the retail market since 1998 and is marked by SPINS research as the top retail line nationwide.

Tümer was the Corporate Communications Manager for SourceOne Global Partners, a Chicago-based nutraceutical company, where she gained her initial experience in the dietary supplement industry. She was responsible for providing support to the company’s clientele, as well as supporting the development and management of marketing and research material distribution. She was also involved in supply chain management. Tümer is a recent graduate of Chicago’s DePaul University, where she studied Communication and Psychology. Self-educated in achieving optimal health status, her strong interest in diet, nutrition and natural health has guided her career path.

“Begüm’s established marketing and customer service skills will be a great benefit to the health care practitioners with whom she works,” stated Kalyna Hanover, Director of Theramedix. “She believes enzymes are essential for overall health and longevity and is determined to expand and share her knowledge with health professionals and their customers.”

Theramedix specializes in enzyme formulations that range in benefit from enhanced absorption of nutrients to systemic immune support. The new line of enzymes will be widely available and represented nationwide as of mid-May. All of Theramedix products are 100% vegan/vegetarian and without any fillers. In addition, each batch is third-party tested for efficacy and label standardization.

Theramedix, a subsidiary of Enzymedica, formulates a premiere line of plant based, pharmaceutical grade enzymes to health care professionals. The Theramedix line is proven to be the highest potency brand and is not available over the counter. The company is based in San Francisco, California with distribution facilities in Venice, Florida. Log onto www.theramedix.net for more information. Media Contact Constance St. John, The St. John Group at 415-454-2243.

Posted by Industrial-Manufacturing at 11:33 PM | Comments (0)